UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30,March 31, 20212022 or

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to _____

 

Commission file number: 000-53166

 

 

 

MusclePharm Corporation

(Exact name of registrant as specified in its charter)

 

Nevada 77-0664193

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

3753 Howard Hughes Parkway6728 W. Sunset Rd. Ste. 130

Suite 200-849


Las Vegas, NV

 8916989118
(Address of principal executive offices) (Zip code)Code)

 

(800(800)) 292-3909859-3010

(Registrant’s telephone number, including area code)

4500 Park Granada, Suite 202

Calabasas, CA91302

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A    

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes YesNo

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes YesNo

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

NumberThe number of shares of the registrant’sissuer’s common stock, $0.001 par value per share, outstanding at August 11, 2021:May 10, 2022 was 33,479,88634,348,891 (excludes 875,621 shares of common stock held in treasury).

 

 

 

MusclePharm Corporation

Form 10-Q

 

TABLE OF CONTENTS

 

  Page
Forward-Looking Statements1
   
PART I – FINANCIAL INFORMATION4
   
Item 1.Financial Statements24
   
 Consolidated Balance Sheets as of June 30, 2021March 31, 2022 (unaudited) and December 31, 2020202124
   
 Consolidated Statements of Operations for the three and six months ended June 30,March 31, 2022 and 2021 and 2020 (unaudited)35
   
 Consolidated Statements of Changes in Stockholders’ Deficit for the three and six months ended June 30,March 31, 2022 and 2021 and 2020 (unaudited)46
   
 Consolidated Statements of Cash Flows for the sixthree months ended June 30,March 31, 2022 and 2021 and 2020 (unaudited)67
   
 Notes to Consolidated Financial Statements (unaudited)78
   
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations2223
   
Item 3.Quantitative and Qualitative Disclosures About Market Risk3130
   
Item 4.Controls and Procedures3130
  
PART II – OTHER INFORMATION32
   
Item 1.Legal Proceedings3532
   
Item 1A.Risk Factors3532
   
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds3532
   
Item 3.Defaults Upon Senior Securities.3632
   
Item 4.Mine Safety Disclosures3632
   
Item 5.Other Information3632
   
Item 6.Exhibits3632
   
 Signatures3733

 

-2-
 

Forward-Looking StatementsCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

Except as otherwise indicated herein, the terms “MusclePharm,” “Company,” “we,” “our” and “us” refer to MusclePharm Corporation and its subsidiaries. This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“(the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the Exchange Act”),use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and Section 27A“would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to:

our business strategies;
the timing of regulatory submissions;
our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;
risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;
risks related to market acceptance of products;
intellectual property risks;
risks associated to our reliance on third party organizations;
our competitive position;
our industry environment;
our anticipated financial and operating results, including anticipated sources of revenues;
assumptions regarding the size of the available market, benefits of our products, product pricing and timing of product launches;
management’s expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and
our cash needs and financing plans.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities Actand Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of 1933,operations. Except as amended. Allrequired by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q other thanwill be deemed to modify or supersede such statements of historical fact, including statements regarding our future results of operations and financial position, including our future profits, financing sources and our ability to satisfy our liabilities, our business strategy and plans, and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict and are subject to a number of risks, uncertainties and assumptions, including those described in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 29, 2021. Moreover, we operate in a very competitive and rapidly changing environment. In particular, we have experienced a slowdown in sales from our retail customers due to the ongoing COVID-19 pandemic, and we cannot predict the ultimate impact of the COVID-19 pandemic on our business. New risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.10-Q.

 

We undertake no obligationThis Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to revise or publicly releasebe reliable, but the resultsaccuracy and completeness of any revision to these forward-looking statements, except as required by law. Given these riskssuch information is not guaranteed. While we believe that such studies and uncertainties, readerspublications are cautionedreliable, we have not to place undue reliance on such forward-looking statements.

Note Regarding Trademarksindependently verified market and industry data from third-party sources.

 

We have proprietary rights to a number of registered and unregistered trademarks worldwide that we believe are important to our business, including, but not limited to: “MusclePharm” and “FitMiss”. We have, in certain cases, omitted the ®, © and ™ designations for these and other trademarks used in this Form 10-Q. Nevertheless, all rights to such trademarks are reserved. These and other trademarks referenced in this Form 10-Q are the property of their respective owners and they will assert, to the fullest extent under applicable law, their rights thereto.

1-3-
 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

 

ITEM 1. FINANCIAL STATEMENTS

MusclePharm Corporation

Consolidated Balance Sheets

(In thousands, except share and per share data)

  (Unaudited)     
 

June 30,

2021

 

December 31,

2020

  (Unaudited)    
  (Unaudited)      March 31, 2022 December 31, 2021 
ASSETS                
Current assets:                
Cash $1,016  $2,003  $534  $1,223 
Accounts receivable, net of allowances of $1,033 and $3,407 at June 30, 2021 and December 31, 2020, respectively  5,564   7,488 
Accounts receivable, net of allowances of $536 and $639 at March 31, 2022 and December 31, 2021, respectively  9,277   6,388 
Inventory  1,561   1,032   975   1,830 
Prepaid expenses and other current assets  2,182   1,341   1,052   1,046 
Total current assets  10,323   11,864   11,838   10,487 
Property and equipment, net  9   13   4   5 
Intangible assets, net  195   356      35 
Operating lease right-of-use assets  338   474   135   203 
Other assets  75   295 
TOTAL ASSETS $10,940  $13,002 
Total Assets $11,977  $10,730 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
Current liabilities:                
Obligation under secured borrowing arrangement $5,297  $7,098 
Line of credit  2,458   743 
Operating lease liability, current  424   381 
Convertible note with a related party, net of discount  2,872   2,872 
Accounts payable  15,218   13,989  $18,877  $17,980 
Accrued and other liabilities  6,806   6,924   6,654   5,942 
Total current liabilities  33,075   32,007 
Operating lease liability, long-term  119   343 
Other long-term liabilities  4,012   5,071 
Total liabilities  37,206   37,421 
Commitments and contingencies (Note 9)        
Obligation under secured borrowing arrangement  6,592   6,446 
Operating lease liability  233   342 
Senior notes payable  7,738   4,555 
Convertible notes with a related party  5,330   5,330 
Revolving line of credit, related party  2,747    
Total Current Liabilities  48,171   40,595 
Other long term liabilities  1,861   2,326 
Total Liabilities  50,032   42,921 
Commitments and contingencies (Note 8)  -     
Stockholders’ deficit:                
Common stock, par value of $0.001 per share; 100,000,000 shares authorized, 34,261,821 and 33,980,905 shares issued as of June 30, 2021 and December 31, 2020, respectively; 33,386,200 and 33,105,284 shares outstanding as of June 30, 2021 and December 31, 2020, respectively  32   32 
Common stock, par value of $0.001 per share; 100,000,000 shares authorized, 33,386,200 and 33,386,200 shares issued as of March 31, 2022 and December 31, 2021, respectively; and 33,386,200 and 33,386,200 shares outstanding as of March 31, 2022 and December 31, 2021, respectively  32   32 
Additional paid-in capital  178,569   178,261   183,792   183,355 
Treasury stock, at cost; 875,621 shares  (10,039)  (10,039)
Treasury Stock at Cost, 875,621 shares  (10,039)  (10,039)
Accumulated deficit  (194,828)  (192,673)  (211,840)  (205,539)
TOTAL STOCKHOLDERS’ DEFICIT  (26,266)  (24,419)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $10,940  $13,002 
Total Stockholders’ Deficit  (38,055)  (32,191)
Total Liabilities and Stockholders’ Deficit $11,977  $10,730 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

2-4-
 

MusclePharm Corporation

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

                 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
  2021  2020  2021  2020 
Revenue, net $14,908  $16,993  $28,029  $33,224 
Cost of revenue  12,728   12,009   22,160   23,431 
Gross profit  2,180   4,984   5,869   9,793 
Operating expenses:                
Advertising and promotion  145   188   489   313 
Salaries and benefits  1,181   1,774   2,229   3,455 
Selling, general and administrative  2,115   1,807   3,512   3,718 
Professional fees  482   865   1,109   1,406 
Total operating expenses  3,923   4,634   7,339   8,892 
Loss from operations  (1,743)  350  (1,470)  901
Other (expense) income:                
Loss on settlement obligation     (37)     (87)
Interest and other expense, net  (501)  (544)  (680)  (1,083)
Loss before provision for income taxes  (2,244)  (231)  (2,150)  (269)
Provision for income taxes  7   22   7   44 
Net loss $(2,251) $(253) $(2,157) $(313)
                 
Net loss per share, basic and diluted $(0.07) $(0.01) $(0.07) $(0.01)
                 
Weighted average shares used to compute net loss per share, basic and diluted  33,386,200   32,764,553   33,131,087   32,612,956 
   2022   2021 
  Three Months Ended 
  March 31, 
  2022  2021 
Revenue, net $13,101  $13,121 
Cost of revenue  11,592   9,432 
Gross profit  1,509   3,689 
Operating expenses:        
Selling and promotion  1,160   1,149 
General and administrative  2,829   2,268 
Total operating expenses  3,989   3,417 
Income (loss) from operations  (2,480)  272 
Other (expense) income:        
Gain on settlements  12   200 
Interest expense  (3,821)  (510)
Other (expense) income, net  (12)  132 
Income (loss) before provision for income taxes  (6,301)  94 
Net income (loss) $(6,301) $94 
Net income (loss) per share, basic $(0.19) $0.00 
Net income (loss) per share, diluted $(0.19) $0.00 
Weighted average shares used to compute net income (loss) per share, basic  33,386,200   33,119,549 
Weighted average shares used to compute net income (loss) per share, diluted  33,386,200   45,492,620 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

3-5-
 

 

MusclePharm Corporation

Consolidated Statements of Changes in Stockholders’ Deficit

(In thousands, except share and per share data)

(Unaudited)

 

                         
        Additional        Total 
  Common Stock  Paid-in  Treasury  Accumulated  Stockholders’ 
  Shares  Amount  Capital  Stock  Deficit  Deficit 
Balance - December 31, 2019  33,000,412  $31  $177,914  $(10,039) $(195,858) $    (27,952)
Stock-based compensation        100         100 
Stock-based compensation, shares                        
Issuance of shares of common stock related to the payment of advertising services  101,454      47         47 
Net loss              (60)  (60)
Balance - March 31, 2020  33,101,866  $31  $178,061  $(10,039) $(195,918) $(27,865)
Stock-based compensation        79         79 
Issuance of shares of common stock related to the payment of advertising services  28,173      69         69 
Net loss              (253)  (253)
Balance – June 30, 2020  33,130,039  $31  $178,209  $(10,039) $(196,171) $(27,970)
                             
  Common Stock  Treasury Stock  Additional Paid-In  Accumulated Other Comprehensive    
  Shares  Amount  Shares  Amount  Capital  Loss  Total 
Balance at December 31, 2020  33,105,284   32   875,621   (10,039)  178,261   (192,673)  (24,419)
Net income                      94   94 
Stock-based compensation for issuance and amortization of restricted stock awards to employees, executives, and directors  280,916   -   -   -   -   -   - 
Balance at March 31, 2021  33,386,200   32   875,621   (10,039)  178,261   (192,579)  (24,325)

                             
  Common Stock  Treasury Stock  Additional Paid-In  Accumulated Other Comprehensive    
  Shares  Amount  Shares  Amount  Capital  Loss  Total 
Balance at December 31, 2021  33,386,200   32   875,621   (10,039)  183,355   (205,539)  (32,191)
Net loss                      (6,301)  (6,301)
Net income (loss)                      (6,301)  (6,301)
Stock-based compensation  -   -   -   -   437   -   437 
Balance at March 31, 2022  33,386,200   32   875,621   (10,039)  183,792   (211,840)  (38,055)

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

4-6-
 

MusclePharm Corporation

Consolidated Statements of Changes in Stockholders’ DeficitCash Flows

(In thousands, except share data)thousands)

(Unaudited)

 

        Additional        Total 
  Common Stock  Paid-in  Treasury  Accumulated  Stockholders’ 
  Shares  Amount  Capital  Stock  Deficit  Deficit 
Balance - December 31, 2020  33,105,284  $32  $178,261  $(10,039) $(192,673) $    (24,419)
Stock-based compensation  280,916                
Net income              94   94 
Balance - March 31, 2021  33,386,200  $32  $178,261  $(10,039) $(192,579) $(24,325)
Balance  33,386,200  $32  $178,261  $(10,039) $(192,579) $(24,325)
Stock-based compensation        308         308 
Net loss              (2,251)  (2,251)
Balance – June 30, 2021  33,386,200  $32  $178,569  $(10,039) $(194,828) $(26,266)
Balance  33,386,200  $32  $178,569  $(10,039) $(194,828) $(26,266)
   2022   2021 
  For the Three Months Ended 
  March 31, 
  2022  2021 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net income/(loss) $(6,301) $94 
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:        
Depreciation and amortization of property and equipment  1   4 
Amortization of intangible assets  35   80 
Bad debt expense  

(355

)  (11)
Provision for inventory write down     86 
Stock-based compensation  437    
Amortization of debt issue cost  419    
OID Interest  568    
Amortization of debt discount  2,196    
Changes in operating assets and liabilities:        
Accounts receivable, net  (2,534)  1,278 
Inventory  855   (406)
Prepaid expenses and other current assets  (6)  527 
Operating lease assets and liabilities  (41)  87 
Accounts payable  897   (1,641)
Other long-term liabilities  (465)   
Accrued and other liabilities  712    
Net cash provided by/(used in) operating activities  (3,582)  98 
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of property and equipment     (4)
Net cash provided by/(used in) investing activities     (4)
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from line of credit     1,061 
Payments on lines of credit     (100)
Proceeds from secured borrowing arrangement, net of reserves  6,293   11,423 
Payments to secured borrowing arrangement, net of fees  (6,147)  (13,781)
Proceeds from revolving line of credit, related party  7,366    
Payments on revolving line of credit, related party  (4,619)   
Repayment of notes payable     (108)
Net cash provided by/(used in) financing activities  2,893   (1,505)
Net increase/(decrease) in cash and cash equivalents  (689)  (1,411)
Cash and cash equivalents, beginning of period  1,223   2,003 
Cash and cash equivalents, end of period $534  $592 
         
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid for interest $3,467  $101 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

5-7-
 

MusclePharm Corporation

Consolidated Statements of Cash Flows

(Unaudited, in thousands)

         
  

Six Months Ended

Jun 30,

 
  2021  2020 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss  $ (2,157) $(313)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation and amortization of property and equipment  6   105 
Amortization of intangible assets  160   160 
Bad debt expense  326   121 
Gain on disposal of property and equipment     (11)
Inventory provision  9   (4)
Stock-based compensation  308   179 
Issuance of common stock to non-employees     116 
Changes in operating assets and liabilities:        
Accounts receivable, net  564   7 
Inventory  (538)  (395)
Prepaid expenses and other current assets  192   21 
Other assets  355   345 
Accounts payable and accrued liabilities  (124)  860 
Net cash (used in) provided by operating activities  (899)  1,191 
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchase of property and equipment  (3)   
Proceeds from disposal of property and equipment     11 
Net cash (used in) provided by investing activities  (3)  11 
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from line of credit  2,192    
Payments on line of credit  (478)  (814)
Proceeds from secured borrowing arrangement, net of reserves  26,211   21,116 
Payments on secured borrowing arrangement  (28,011)  (22,639)
Proceeds from issuance of Paycheck Protection Program Loan     965 
Repayment of finance lease obligations     (52)
Proceeds of notes payable  186     
Repayment of notes payable  (185)  (97)
Net cash used in financing activities  (85)  (1,521)
         
NET CHANGE IN CASH  (987)  (319)
CASH — BEGINNING OF PERIOD  2,003   1,532 
CASH — END OF PERIOD  $ 1,016  $1,213 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid for taxes $681  $402 

The accompanying notes are an integral part of these Consolidated Financial Statements.

6

MusclePharm Corporation

Notes to the Consolidated Financial Statements

(Unaudited)(dollars in thousands, unless otherwise indicated)

 

Note 1. Description of Business

 

Description of Business

 

MusclePharm Corporation, together with its subsidiaries (the “Company” or “MusclePharm”) is a scientifically-driven, performance lifestyle company that develops, markets and distributes branded sports nutrition products and nutritional supplements that are manufactured by the Company’s co-manufacturers. Ourcontract manufacturers. The Company’s portfolio of recognized brands, including MusclePharm, FitMiss and FitMiss,MP Combat Energy is marketed and sold globally. As of March 31, 2022, the Company had the following wholly-owned subsidiary which did not have any operations or assets as of and for the three months ended March 31, 2022: MusclePharm Canada Enterprises Corp.

In 2021, the Company announced its entrance into the functional energy space in collaboration with former Rockstar Energy executives. The Company launched three flavors of MP Combat Energy in September 2021 for domestic distribution and three additional flavors for international distribution. The Company believes the launch of its new energy products, reductions in operating costs and continued focus on gross profit and revenue growth will allow it to ultimately achieve sustained profitability. However, the Company can give no assurances that this will occur, especially with the cost to launch new energy products along with the recent increase in the cost of protein, which may have a material impact on the Company’s profitability. Additionally, the Company’s profitability may be materially impacted by the ability of the Company’s contract manufacturers to meet customers’ demands. Although, the Company believes entering the functional energy space will help to increase sales and gross margin, and reduce exposure to commodity prices, the Company can give no assurances that this will occur. To manage cash flow, the Company has entered into multiple financing arrangements. The entry into the Energy Drink business has created a second segment, which is presented in detail in Note 12.

Information About Our Segments

We are engaged in global sales of products that fall into two operating segments: Protein Products and Energy Drinks. Information regarding our operating segments and geographic and product information is contained in Note 12 to these consolidated financial statements.

Going Concern

 

The Company has historically incurred significant losses and experienced negative cash flows since inception. As of June 30, 2021,March 31, 2022, the Company had cash of $1.00.5 million, an increase of $0.4 million from March 31, 2021 and a decline of $1.0 million from the December 31, 2020 balance of $2.0 million. As of June 30, 2021, the Company had a working capital deficit of $22.8 36.3million, a stockholders’ deficit of $2638.1 .3 million and an accumulated deficit of $194.8211.8 million resulting from recurring losses from operations. As a result of oura history of losses and financial condition, there is substantial doubt about ourthe Company’s ability to continue as a going concern.

 

The Company’s ability to continue as a going concern is dependent upon it generating profits in the future and/or obtaining the necessary financing to meet its obligations and repay liabilities arising from normal business operations when they come due. The Company is evaluating different strategies to obtain financing to fund its operations to cover expenses and focus on achieving a level of revenue adequate to support its current cost structure. Financing strategies may include, but are not limited to, private placementsissuances of capital stock, debt borrowings, partnerships and/or collaborations.

 

The Company has been focused on cost containment and improving gross margins by focusing on customers with higher margins, reducing product discounts and promotional activity, along with reducing the number of SKU’s and negotiatenegotiating improved pricing for raw materials. In addition, the Company has worked to negotiate lower production costs with its co-manufacturers.contract manufacturers. Although these steps improved gross margins through the first quarter of 2021,2022, with the recent further increases in commodity prices, primarily protein, the company’sCompany’s gross margins have been impacted and will continue to be impacted unless commodity prices return the same levels that were seen in 2020.2021. The Company expects overall margins to improve as we ramp up energy sales with stronger gross margins in the energy drink segment.

 

-8-

In 2021, the Company announced its entrance into the functional energy space with its partnership with a former Rockstar Energy executive. The Company plans to launch 3 new energy products in the summer of 2021. The Company believes with the launch of its new energy products, reductions in operating costs and continued focus on gross profit and top line sales growth will allow it to ultimately achieve sustained profitability. However, the Company can give no assurances that this will occur, especially with the cost to launch new energy products along with the recent increase in the cost of protein, which may have a material impact on the Company’s profitability. Additionally, the Company’s profitability may be materially impacted by the ability of our third-party manufacturers to meet our customers’ demands. Although, the Company believes entering the functional energy space will help to increase sales and gross margin, and reduce exposure to commodity prices, the Company can give no assurances that this will occur. To manage cash flow, the Company has entered into multiple financing arrangements.

COVID-19

The Company’s results of operations are affected by economic conditions, including macroeconomic conditions and levels of business confidence. There continues to be significant volatility and economic uncertainty in many markets and the ongoing COVID-19 pandemic contributes to that level of volatility and uncertainty and has created economic disruption. The Company is actively managing its business to respond to the impact. There were no adjustments recorded in the financial statements that might result from the outcome of these uncertainties.

 

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on ourthe Company’s business, financial condition and results of operations. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expense.

7

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The Company’s management believes the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2021,March 31, 2022, results of operations for the three and six months ended June 30, 2021 and 2020, and cash flows for the sixthree months ended June 30, 2021March 31, 2022 and 2020.2021. The results of operations for the three and six months ended June 30, 2021March 31, 2022 are not necessarily indicative of the results to be expected for the year ended December 31, 2021.2022.

 

These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K as amended for the year ended December 31, 2020,2021, filed with the SEC on March 29, 2021.May 4, 2022.

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory, the calculation of the Company’s effective tax rate and deferred tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets,stock based compensation, warrants, likelihood and range of possible losses on contingencies and present value of lease liabilities, among others.liabilities. Actual results could differ from those estimates.

Shipping and handlingDisaggregation of Revenue

 

The Company accountsfollowing shows the disaggregation of revenue by distribution channel for shippingthe three months ended March 31, 2022 and handling costs as fulfillment activities, which are therefore recognized upon shipment of the goods.2021 (in thousands).

Schedule of Disaggregation of Revenue

  For the Three Months Ended March 31, 
  2022  % of Total  2021  % of Total 
Distribution Channel                
Specialty $3,383   26% $6,795   52%
International  733   6%  3,847   29%
FDM  8,985   68%  2,479   19%
Total $13,101   100% $13,121   100%

For the three and six months ended June 30, 2021 the Company incurred $0.5  million and $1.0 million, respectively, of inbound shipping and handling costs. For the three and six months ended June 30, 2020 the Company incurred $0.4 million and $0.8 million, respectively, of inbound shipping and handling costs. Shipping and handling costs related to inbound purchases of raw material and finished goods are included in cost of revenue in our consolidated statements of operations.

For the three and six months ended June 30, 2021, the Company incurred $0.9 million and $1.6 million, respectively, of shipping and handling costs related to shipments to our customers. For the three and six months ended June 30, 2020, the Company incurred $0.6 million and $1.2 million, respectively, of shipping and handling costs related to shipments to our customers. Shipping and handling costs related to shipments to our customers is included in “Selling, general and administrative” expense in our consolidated statements of operations.

8-9-
 

Sales discounts and returnsConcentrations

The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. During the three months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $1.9 million and $3.6 million, respectively, which accounted for 11% and 17% of gross revenue in each period, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $4.4 million and $7.6 million, respectively, which accounted for 14% and 19% of gross revenue in each period, respectively.

Concentrations

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The Company maintains its cash balance at credit-worthy financial institutions that aretimes may exceed federally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. There was an aggregate uninsured cash balance of $0.8 million as of June 30, 2021.limits. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

Significant customers and vendors are those that represent more than 10% of the Company’s net revenue net or accounts receivable for each period presented.

 

ForDuring the three months ended June 30, 2021, the Company had two customers who individually accounted for 55% and 13% of net revenue. For the six months ended June 30, 2021, the CompanyMarch 31, 2022, we had three customers who individually accounted for 43%59%, 13%, and 13%12% of our net revenue. One customerrevenue, and two customers that individually accounted for 59% and 17% of accounts receivable, net as of June 30, 2021.

Forreceivable. During the three months ended June 30, 2020, the CompanyMarch 31, 2021, we had three customers who individually accounted for 30%28%, 24%17% and 21%14% of our net revenue. For the six months ended June 30, 2020, the Company had threerevenue, and two customers whothat individually accounted for 33%32% , 23% and 16%21% of net revenue. Three customers accounted for 31%, 18% and 16% of accounts receivable, net as of June 30, 2020.

receivable.

The Company uses a limited number of non-affiliated suppliers for contract manufacturing of its products. ForThe Company has quality control and manufacturing agreements in place with its primary manufacturers to ensure consistency in production and quality. The agreements ensure products are manufactured to the Company’s specifications and the contract manufacturers will bear the costs of recalled products due to defective manufacturing. During the three months ended June 30,March 31, 2022, the Company had four vendors who individually accounted for 17%, 12%, 12%, and 11% of net purchases, respectively. During the three months ended March 31, 2021, the Company had three suppliersvendors who individually accounted for approximately 23%32%, 15% 21%and 13% 21%of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2021, the Company had three suppliers who individually accounted for approximately 24%, 15% and 15% of its purchases with contract manufacturers and raw material providers. Four customers accounted for 33%, 17%, 12% and 11% of accounts payable as of June 30, 2021.net purchases.

 

ForThe Company has a geographic concentration in the United States, with 94% and 71% of revenue from domestic customers during the three months ended June 30, 2020,March 31, 2022 and 2021, respectively. International customers, primarily in Canada and Asia, comprised 6% and 29% for the three months ended March 31, 2022 and 2021, respectively.

Segments

Historically, the Company’s chief operating decision maker (“CODM”) reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. As such, the Company has had three suppliers who individually accounted for approximately 33%, 30% two reporting segments and 20% operating unit structures. During the fourth quarter of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2020,2021, the Company had three suppliers who individually accounted for approximately 34%, 30% introduced a functional energy beverages line under the MusclePharm and 17% of its purchasesFitMiss brands, so the CODM now reviews financial information and makes resource and opportunity decisions on a disaggregated basis with contract manufacturers and raw material providers. Three customers accounted for 19%, 12% and 12% of accounts payable as of June 30, 2020.the functional energy drink business separate from protein products.

 

Recent Accounting PronouncementsLitigation Estimates and Accruals

 

In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. The Company provides disclosures for material contingencies when there is a reasonable possibility that a loss or an additional loss may be incurred. In assessing whether a loss is a reasonable possibility, the Company may consider the following factors, among others: the nature of the litigation, claim or assessment, available information, opinions or views of legal counsel and other advisors, and the experience gained from similar cases.

Income Taxes

Income taxes are accounted for using the asset and liability method. Income tax expense includes the current tax liability from operations and the change in deferred income taxes during the year. Interest income, interest expense and penalties associated with income taxes are reflected in (Benefit) provision for income taxes on the consolidated statements of operations. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

A valuation allowance is required to be established unless management determines that it is more likely than not that the Company will ultimately realize the tax benefit associated with a deferred tax asset. The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

-10-

Recent Accounting Pronouncements

In July 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments(“ (“ASU 2016-13”), which requires the measurement of all expected credit losses of financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. In addition, the ASU amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 is effective for periods beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.

 

9

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). The amendments in this ASU apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate that is expected to be discontinued because of reference rate reform. The amendments in this update provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for hedging relationships existing as of December 31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. The amendments in this ASU are effective for all entities as of March 12, 2020, through December 31, 2022. The Company has not modified any material contracts due to reference rate reform. The Company will continue to evaluate the impact this guidance will have on its consolidated financial statements for all future transactions affected by reference rate reform during the time permitted.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20)and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The FASB also specified that an entity should adopt the guidance as of the beginning of its annual fiscal year and is not permitted to adopt the guidance in an interim period. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. EarlyThere has not been a significant impact from the adoption is permitted. The Company is currently evaluating the impactof this ASU may have on itsthe consolidated financial statements.

 

Recently Adopted Accounting PronouncementsReclassifications

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which was expected to reduce cost and complexity related to the accounting for income taxes. The ASU removes specific exceptions to the general principles in Topic 740 in U.S. GAAP. It eliminates the need for an organization to analyze whether the following apply in a given period: exception to the incremental approach for intra-period tax allocation; exceptions to accounting for basis differences when there are ownership changes in foreign investments; and exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also simplifies U.S. GAAP for: franchise taxes that are partially based on income; transactions with a government that result in a step up in the tax basis of goodwill; separate financial statements of legal entities that are not subject to tax; and enacted changes in tax laws in interim periods. The Company adopted this ASU effective January 1, 2021, with certain provisions applied retrospectively and other provisions applied prospectively. Adoption of this ASU did not have a material impact to the Company’s condensed consolidated balance sheet, statements of operations, or cash flows.

Reclassifications.

Certain prior period amounts have been reclassified to conform to the current period financial statement presentations,presentation, including classification of certain labilities. These changes in presentation did not have a material impact on the Company's financial condition or results of operations.operating expenses.

 

Note 3. Inventory

 

Inventory consisted solelyconsists of finished goods and raw materials used to manufacture ourthe Company’s products by one of our co-manufacturers (in thousands):contract manufacturers for the three months ended March 31, 2022 and 2021. The Company records charges for obsolete and slow-moving inventory based on the age of the product as determined by the expiration date or otherwise determined to be obsolete. Products within one year of their expiration dates are considered for write-off purposes. Inventory write-downs, once established, are not reversed as they establish a new cost basis for the inventory. Historically, the Company has had minimal returns with established customers. The Company accounts for its inventory on a First-in First-out basis.

Schedule of Inventory

  

As of

June 30, 2021

  

As of

December 31, 2020

 
Raw materials $625  $332 
Finished goods  936   700 
Inventory $1,561  $1,032 

10-11-
 

The components of inventory as of March 31, 2022 and December 31, 2021 were as follows (in thousands):

Schedule of Inventory

  March 31, 2022  December 31, 2021 
Raw Materials $746  $694 
Finished Goods  229   1,144 
Inventory  975   1,838 
Less: inventory writedown     (8)
Inventory $975  $1,830 

 

Note 4. Accrued and Other Liabilities

 

As of June 30, 2021March 31, 2022 and December 31, 2020,2021, the Company’s accrued and other liabilities consisted of the following (in thousands):

 Schedule of Accrued and Other Liabilities

 

As of

June 30, 2021

 

As of

December 31, 2020

  March 31, 2022  December 31, 2021 
Accrued professional fees $114  $242  $342  $236 
Accrued interest  748   644   1,151   797 
Accrued payroll and bonus  630   738   702   695 
Settlements – short-term (Nutrablend and 4Excelsior)  2,949   2,735 
Accrued expenses - ThermoLife  1,364   1,364 
Settlements — short term (Nutrablend and 4Excelsior)  2,102   2,104 
Accrued expenses — ThermoLife  1,364   1,364 
Accrued and other short-term liabilities  

1,001

   1,201   993   746 
Accrued and other liabilities $6,806  $6,924 
Total accrued and other liabilities $6,654  $5,942 

Note 5. Interest and other expense, netExpense

 

For the three months ended June 30,March 31, 2022 and March 31, 2021, and 2020, “Interest and otherinterest expense net” consisted of the following (in thousands):following:

 Schedule of Interest and Other Expense, NetExpenses

                 
  

For the

Three Months

Ended June 30,

  

For the

Six Months

Ended June 30,

 
  2021  2020  2021  2020 
             
Interest expense, related party $(147) $(76) $(282) $(152)
Interest expense, other  (235)  (175)  (443)  (332)
Interest expense, secured borrowing arrangement  (258)  (383)  (424)  (748)
Foreign currency transaction loss  34   16   32   (18)
Other  105   74   437   167 
Total interest and other expense, net $(501) $(544) $(680) $(1,083)

“Other” includes sublease income.

Note 6. Leases

A summary of the Company’s lease portfolio as of June 30, 2021 and December 31, 2020 is presented in the table below (in thousands):

Schedule of Supplemental Balance Sheet Information

  Balance Sheet Classification June 30, 2021  December 31, 2020 
Assets          
Operating ROU assets, net $338  $474 
           
Liabilities          
Current liabilities:          
Operating Operating lease liability - current $424  $381 
           
Non-current liabilities:          
Operating Operating lease liability - long term  119   343 
Total lease liabilities   $543  $724 

11

Supplemental cash flow information related to leases was as follows:

Schedule of Supplemental Cash Flow Information

  Six months ended June 30, 2021  Six months ended June 30, 2020 
Cash paid for amounts included in the measurement of lease liabilities (in thousands):        
Operating cash flows from operating leases $180  $397 
Operating cash flows from finance leases     1 
Financing cash flows from finance leases     52 
         
The weighted average remaining lease term was as follows:        
Operating leases (in years)  1.2   2.0 
Finance leases (in years)     0.1 
The weighted average discount rate was as follows:        
Operating leases  18%  18%
Finance leases     5%
       
  For the Three Months Ended March 31, 
  2022  2021 
Interest expense, related party $(313) $(120)
Interest expense, other  (254)  (227)
Interest expense, secured borrowing arrangement  (71)  (163)
Amortization of debt issue cost associated with related warrants  (2,615)  - 
Amortization of debt issue cost - OID  (568)  - 
Total interest expense $(3,821) $(510)

Note 7.6. Other Long-TermLong -Term Liabilities

As of June 30, 2021,March 31, 2022 and December 31, 2020,2021 the Company’s other long-term liabilities consisted of the following (in thousands):

 Schedule of Other Long-Term Liabilities

  

As of

June 30, 2021

  

As of

December 31, 2020

 
Settlements – long-term (Nutrablend and 4Excelsior)  3,143   3,906 
Paycheck Protection Program loan  643   965 
Other     200 
Other long-term debt $3,786  $5,071 
  As of March 31, 2022  As of December 31, 2021 
Settlements — long term (Nutrablend and 4Excelsior) $1,861  $2,326 
Total other long term liabilities $1,861  $2,326 

-12-

Note 7. Debt

As of March 31, 2022 and December 31, 2021, the Company’s debt consisted of the following (in thousands):

Schedule of Debt

  March 31, 2022  December 31, 2021 
Senior notes payable $

7,798

  $5,034 

Debt issue costs, net

  

(60

)  (479)
Refinanced convertible note, related party  5,330   5,330 
Revolving line of credit, related party  2,747   - 
Obligations under secured borrowing arrangement  6,592   6,446 
Total current debt $22,407  $16,331 

Senior Notes Payable

 

Note 8. On October 13, 2021, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors as purchasers (the “Investors”). Pursuant to the Securities Purchase Agreement, the Company sold, and the Investors purchased, $Debt8.2 million (the “Purchase Price”) in principal amount of senior notes (the “Senior Notes”) and warrants (the “Warrants”).

The Senior Notes were issued with an original issue discount of 14%, bear no interest and mature after 6 months, on April 13, 2022. To secure its obligations thereunder and under the Securities Purchase Agreement, the Company has granted a security interest over substantially all of its assets to the collateral agent for the benefit of the Investors, pursuant to a pledge and security agreement.

The maturity date of the Senior Notes was extended to May 28, 2022, on April 12, 2022. The maturity date of the Senior Notes also may be extended under other circumstances specified therein. Subsequent to the extension, interest accrued from April 13, 2022 at 18% per annum until the Senior Notes are paid in full. The Company is undertaking various initiatives to improve gross margins to become cash flow positive prior to the maturity of the Senior Notes. These initiatives include improving cost of goods sold on certain raw materials. There can be no assurance the Company will be able to successfully implement such initiatives on a timely basis or at all or that it otherwise will meet the conditions required to extend the Senior Notes. If the Company is unable to extend the Senior Notes or elects not to do so, the Company will be required to repay the Senior Notes through equity issuances, additional borrowings, cash flows from operations and/or other sources of liquidity.

-13-

The Warrants are exercisable for five (5) years to purchase 18,463,511 shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $0.78, subject to adjustment under certain circumstances described in the Warrants. The Warrants have a face value of $4.4 million which is recorded in Additional Paid-In Capital.

In conjunction with the private placement of Senior Notes and Warrants, each of the directors and officers of the Company entered into lock-up agreements, which prohibited sales of the Common Stock until after April 11, 2022, subject to certain exceptions.

The issuance of the Senior Notes and Warrants was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as additional paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction.

 

Related-Party RefinancedNovember 2020 Convertible Note, Related Party

 

On November 29, 2020, the Company entered into a refinancing agreement with Mr. Ryan Drexler, the Company’s Chairman of the Board of Directors and Chief Executive Officer (the “November 2020 Refinancing”), in which the Company issued to Mr. Drexler a convertible secured promissory note (the “NovemberNovember 2020 Convertible“Convertible Note”) in the original principal amount of $2,871,9672.9, million, which amended and restated a convertible secured promissory note dated as of August 21, 2020. The $2.9 million November 2020 Convertible Note bears interest at the rate of 12% per annum. Unless earlier converted or repaid, all outstanding principal and any accrued but unpaid interest under the November 2020 Convertible Note wasshall be due and payable on July 1, 2021;2021, however the Company and Mr. Drexler agreed to an extension on August 13, 2021 until July 14, 2022 (see Note 14. Subsequent Events).2022. Any interest not paid when due shall be capitalized and added to the principal amount of the November 2020 Convertible Note and bear interest on the applicable interest payment date along with all other unpaid principal, capitalized interest, and other capitalized obligations.

 

Mr. Drexler may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price of $0.23 per share. At the election of the Company, one-sixth of the interest may be paid in kind (“PIK Interest”) by adding such amount to the principal amount of the note, or through the issuance of shares of the Company’s common stock to Mr. Drexler. The PIK Interest is convertible to common stock at the closing price per share on the last business day of each calendar quarter. In no event will the conversion price of such PIK Interest be less than $0.10. The Company may prepay the Note by giving Mr. Drexler between 15-15-days’ and 60-days’ notice depending upon the specific circumstances, subject to Mr. Drexler’s conversion right. The Company intends to pay all interest due on the Convertible Note to Mr. Drexler at the end of each calendar quarter.

 

The November 2020 Convertible Note contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the November 2020 Convertible Note. The November 2020 Convertible Note is subordinated to the secured borrowing arrangementcertain other indebtedness of the Company entered into withheld by Prestige Capital Corporation (“Prestige”). and the Senior Notes.

-14-

 

For the three months ended June 30,March 31, 2022 and 2021, and 2020, interest expense related to the related party convertible secured promissory note was $0.10.085 million and $0.10.085 million, respectively. During the three months ended March 31, 2022, no interest was paid in cash to Mr. Drexler; during the three months ended March 31, 2021 $0.085 million of interest was paid in cash to Mr. Drexler.

 

For the six months ended June 30,August 2021 and 2020, interest expense related to the related party convertible secured promissory note was $0.2 million and $0.2 million, respectively.

12

Convertible Note, Related Party

Related-Party Secured Revolving Promissory Note

On October 15, 2020, the Company entered into a secured revolving promissory note (the “Revolving Note”) with Mr. Ryan Drexler. Under the terms of the Revolving Note, the Company can borrow up to $3.0 million. The Revolving Note bears interest at the rate of 12% per annum. The funds were used for the purchase of whey protein and other general corporate purposes. Both the outstanding principal, if any, and all accrued interest under the Revolving Note were due on March 31, 2021; however,2021, which was not paid.

On August 13, 2021, the Company issued to Ryan Drexler (the “Holder”) a convertible secured promissory note (the “August 2021 Convertible Note”) in the original principal amount of $2.5 million, replacing the Revolving Note.

The August 2021 Convertible Note bears interest at the rate of 12% per annum. Interest payments are due on the last day of each calendar quarter. At the Company’s option (as determined by its independent directors), the Company may repay up to one sixth of any interest payment by either adding such amount to the principal amount of the August 2021 Convertible Note or by converting such interest amount into an equivalent amount of the Company’s common stock, $0.001 par value per share (the “Common Stock”). Any interest not paid when due shall be capitalized and Mr. Drexler agreedadded to an extension until June 30,the principal amount of the August 2021 Convertible Note and bear interest on the applicable interest payment date along with all other unpaid principal, capitalized interest, and other capitalized obligations. Both the principal and any accrued but unpaid interest under the August 2021 Convertible Note will be due on July 14, 2022, (see Note 14. Subsequent Events).unless converted or repaid earlier.

The Holder may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price equal to the closing price of the common stock on October 15, 2021. The Company may prepay the RevolvingAugust 2021 Convertible Note by giving Mr. Drexler onethe Holder between 15 and 60 days’ advance written notice. notice depending upon the specific circumstances, subject to the Holder’s conversion right.

The RevolvingAugust 2021 Convertible Note contains customary events of default, including, among others, the failure by the Company to make a payment of principal or interest when due. Following an event of default, Mr. Drexler is entitledat the option of the Holder and upon written notice to accelerate the entire indebtednessCompany, or automatically under the Revolving Note.certain circumstances, all outstanding principal and accrued interest will become due and payable. The RevolvingAugust 2021 Convertible Note also contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the RevolvingAugust 2021 Convertible Note. The RevolvingAugust 2021 Convertible Note is subordinated to the secured borrowing arrangement the Company entered into with Prestige. In connection with the Revolving Note, the Company and Mr. Drexler entered into a fifth amended and restated security agreement dated October 15, 2020 (the “Security Agreement”) pursuant to which the Revolving Note is secured by all of the assets and propertiescertain other indebtedness of the Company held by Prestige Corporation (“Prestige”) and its subsidiaries whether tangible or intangible.the Senior Notes.

 

-15-

As of June 30, 2021,

For the outstanding balance onthree months ended March 31, 2022, interest expense related to the revolvingrelated party convertible secured promissory note was $2.50.122 million.million and there was 0 interest expense related to this note for the three months ended March 31, 2021. During the three and six months ended June 30,March 31, 2022 and 2021 0interest was paid in cash to Mr. Drexler.

Revolving Line of Credit, Related Party

On March 8, 2022, the Company entered into an Unsecured Revolving Promissory Note (the “Note”) with the Mr. Ryan Drexler. Under the terms of the Note, proceeds may be used solely to finance the production of orders from its largest customer or any of its affiliates or subsidiaries. The Note does not contain a cap on borrowings thereunder. However, further advances under the Note are at the discretion of the Lender. Outstanding balances under the Note accrue interest at the rate of 18% per annum. Prior to maturity, the Company generally may pay down principal balances and re-borrow under the Note, subject to the discretion of the Lender to advance funds under the Note. The Note contains customary events of default and acceleration provisions.

The Note is subordinate to the 14% Original Issue Discount Senior Secured Notes previously issued by the Company. Under the terms of the First Amendment to Intercreditor and Subordination Agreement, dated as of March 8, 2022, between the Company, Ryan Drexler and Empery Tax Efficient, LP (the “Amendment”), principal but not interest due under the Note generally may be repaid out of payments received by the Company in respect of accounts receivable financed pursuant to the Note.

The related party revolving line of credit balance as of March 31, 2022 was $0.12.7 million and was 0 on at March 31, 2021.

For the three months ended March 31, 2022 and 2021 total related party debt was $8.1 million and $0.14.6 million, respectively.

 

For the three months ended March 31, 2022, interest expense related to the revolving line of credit, related party was $0.106 million.

Obligations Under Secured Borrowing Arrangement

 

In January 2016, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) with Prestige, pursuant to which the Company agreed to sell and assign, and Prestige agreed to buy and accept, certain accounts receivable owed to the Company (“Accounts”). Under the terms of the Purchase and Sale Agreement, upon the receipt and acceptance of each assignment of Accounts, Prestige will pay the Company 80% of the net face amount of the assigned Accounts, up to a maximum total borrowing of $12.5 million subject to sufficient amounts of accounts receivable to secure the loan. The remaining 20% will be paid to the Company upon collection of the assigned Accounts, less any chargebacks (including chargebacks for any customer amounts that remain outstanding for over 90 days), disputes, or other amounts due to Prestige. Prestige’s purchase of the assigned Accounts from the Company will be at a discount fee which varies from 0.7% to 4%, based on the number of days outstanding from the assignment of Accounts to collection of the assigned Accounts. In addition, the Company granted Prestige a continuing security interest in and first priority lien upon all accounts receivable, inventory, fixed assets, general intangibles, and other assets. Prestige will have no recourse against the Company if payments are not made due to the insolvency of an account debtor within 90 days of invoice date, with the exception of international and certain domestic customers.customers. On April 10, 2019, the Company and Prestige amended the terms of the agreement. The agreement was extended until April 1, 2020 and automatically renews for one (1) year periods unless either party receives written notice of cancellation from the other, at minimum, thirty (30) days prior to the expiration date thereafter.thereafter.

 

On June 14, 2021, Prestige advanced the Company $11.0 million with a six-month term, 15% interest rate and 2% accommodation fee.

As of June 30, 2021, and December 31, 2020, the Company had outstanding borrowings under the secured borrowing arrangement of approximately $5.3 million and $7.1 million, respectively.

 

DuringOn July 26, 2021, Prestige advanced the Company $1.0 million with a six-month term and a 15% interest rate. In addition, there was an accommodation fee equal to 1% of the amount advanced plus 18,750 stock options.

On October 12, 2021, the June 14, 2021 and July 26, 2021 the total Prestige advance $2.0 million was extended to the date of the termination of the senior secured note offering, which is in April 2022, and was extended to May 28 2022.

For the three months ended June 30,March 31, 2022 and 2021, and 2020, the Company assigned to Prestige accounts with an aggregate face amount of approximately $18.56.3 million and $14.811.4 million, respectively, for which Prestige paid torespectively. For the three months ended March 31, 2022 and 2021, the Company approximatelymade payments to Prestige in the amounts of $14.76.1 million and $11.713.8 million, respectively, in cash. During the three months ended June 30,As of March 31, 2022 and December 31, 2021, and 2020,we had outstanding borrowings of approximately $14.26.6 million and $12.66.4 million, respectively, was repaid to Prestige, including fees and interest.respectively.

 

13-16-
 

During the six months ended June 30, 2021 and 2020, the Company assigned to Prestige, accounts with an aggregate face amount of approximately $32.8 million and $26.4 million, respectively, for which Prestige paid to the Company approximately $26.2 million and $21.1 million, respectively, in cash. During the six months ended June 30, 2021 and 2020, $28.0 million and $22.6 million, respectively, was repaid to Prestige, including fees and interest.

Paycheck Protection Program Loan

 

Due to economic uncertainty as a result of the ongoing pandemic (COVID-19)(“COVID-19”), on May 14, 2020, the Company received an aggregate principal amount of $964,910 pursuant to the borrowing arrangement (“Note”) with Harvest Small Business Finance, LLC (“HSBF”) and agreed to pay the principal amount plus interest at a 1% fixed interest rate per year, on the unpaid principal balance. The Note includes forgiveness provisions in accordance with the requirements of the Paycheck Protection Program, Section 1106 of the CARES Act.

 

The Note iswas expected to mature on May 16, 2025.2025. Payments were due by November 16, 2020 (the “Deferment Period”) and interest was accrued during the Deferment Period.Period. However, the Flexibility Act, which was signed into law on June 5, 2020, extended the Deferment Period to the date that the forgiven amount is remitted by the United States Small Business Administration (“SBA”) to HSBF. The Company is in the process of filling out the forgiveness application form.

As of June 30,

On October 25, 2021, the Company owed approximatelyreceived a letter from HSBF indicating the Company’s SBA PPP loan has been forgiven in full by HSBF and was recorded as a $1.0 964,910million (principal plus accrued interest), which $0.1M is classified as “short-term” and the remaining amount is recorded within “Other long-term liabilities.” gain on forgiveness of debt located in other income-loan forgiveness.

Note 9.8. Commitments and Contingencies

 

SettlementsContingencies

 

Manchester City Football Group

The Company was engaged in a dispute with City Football Group Limited (“CFG”), the owner of Manchester City Football Group, concerning amounts allegedly owed by the Company under a sponsorship agreement with CFG (the “Sponsorship Agreement”). In August 2016, CFG commenced arbitration in the United Kingdom against the Company, seeking approximately $8.3 million for the Company’s purported breach of the Sponsorship Agreement.

On July 28, 2017, the Company approved a Settlement Agreement (the “CFG Settlement Agreement”) with CFG effective July 7, 2017. The CFG Settlement Agreement represents a full and final settlement of all litigation between the parties. Under the terms of the agreement, the Company agreed to pay CFG a sum of $3 million, which was recorded as accrued expenses in 2017. The settlement consists of a $1 million payment that was advanced by a related party on July 7, 2017, a $1 million installment paid on July 7, 2018 and a subsequent $1 million installment payment to be paid by July 7, 2019. Of this amount, the Company has remitted $0.3 million.

During the three months ended June 30, 2021 and 2020, the Company recorded a charge of $19,000 and $19,000, respectively and during the six months ended June 30, 2021 and 2020, the Company recorded a charge of $38,000 and $38,000, respectively. This charge, representing imputed interest, is included in “Interest and other expense, net” in the Company’s consolidated statements of operations.

Nutrablend Matter

On February 27, 2020, Nutrablend, a manufacturer of MusclePharm products, filed an action against the Company in the United States District Court for the Eastern District of California, claiming approximately $3.1 million in allegedly unpaid invoices. These invoices relate to the third and fourth quarter of 2019, and a liability has been recorded in the books for the related periods.

On September 25, 2020, the parties successfully mediated the case to a settlement (the “Nutrablend Agreement”) and the Company agreed to (i) pay approximately $3.1 million (“Owed Amount”) in monthly payments (“Monthly Payments”) from September 1, 2020 through June 30, 2023 and (ii) issue monthly purchase orders (“Purchase Orders”) at minimum amounts accepted by Nutrablend.

14

The Company agreed to issue Purchase Orders in a combined total amount of at least (i) $1,500,000 from September 1, 2020 through November 30, 2020; (ii) $1,800,000 from December 1, 2020 through February 28, 2021; (iii) $2,100,000 from March 31, 2021 through May 31, 2021; (iv) $2,100,000 from June 1, 2021 through August 31, 2021; and (v) $1,400,000 from September 1, 2021 through October 30, 2021. Beginning on November 1, 2021, the Company will be required to issue monthly Purchase Orders to Nutrablend in a minimum amount of $700,000 until the Owed Amount is paid in full to Nutrablend. In the event that the Company pays the Owed Amount in full before September 1, 2021, its entitled to a rebate on all completed Purchase Orders. Further, once the monthly payments, and any additional payments that the Company has made on the Owed Amount, reduce the outstanding balance of the Owed Amount to below $2.0 million, the Company is eligible for an extension of a line of credit from Nutrablend in an amount of up to $3.0 million.

On July 7, 2021, the Company commenced an action against Nutrablend in the Central District of California, seeking (i) a declaration that the Nutrablend Agreement purchase order provisions have been terminated due to Nutrablend’s failure to provide the Company with reasonable assurances of its ability to fulfill its purchase orders; (ii) a declaration that approximately $2.0 million in purchase orders that the Company placed in July and August 2020 were intended to and do count towards the minimums set forth in the Nutrablend Agreement; and (iii) damages based on Nutrablend’s failure to fulfill purchase orders. The case is ongoing.

The Company determined that approximately $1.1 million dollars of the Owed Amount was due within a year, and this amount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Owed Amount that was due after a year was $1.0 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company made payments of $0.7  million as of June 30, 2021.

During the three and six months ended June 30, 2021 the Company recorded interest of $0.1 million and $0.1 million, respectively. This charge, representing imputed interest, is included in “Interest and other expense, net” in the Company’s consolidated statements of operations.

4Excelsior Matter

On March 18, 2019, Excelsior Nutrition, Inc. (“4Excelsior”), a manufacturer of MusclePharm products, filed an action against the Company in the Superior Court of the State of California for the County of Los Angeles, claiming approximately $6.2 million in damages relating to allegedly unpaid invoices, as well as approximately $7.8 million in consequential damages.

On December 16, 2020, the Company and 4Excelsior entered into a Settlement Agreement and Mutual Release (“the Agreement”), pursuant to which the parties resolved and settled the civil action pending in the Superior Court of the State of California for the County of Los Angeles (the “Litigation”). The parties agreed to a mutual general release of claims and to jointly file within 10 business days of the effective date of the Agreement a stipulation and proposed order of dismissal, dismissing with prejudice all claims and counterclaims asserted in the Litigation. The Company agreed to pay $4.75 million (the “Settlement Amount”) in four monthly payments of $70,000, beginning January 5, 2021, and thereafter in monthly payments of $0.1 million until the Settlement Amount is fully paid. The Company may prepay all or any portion of the Settlement Amount at any time without penalty or premium. The Agreement provides that, in the event of a Default (as defined in the Agreement) by the Company, the entire outstanding balance of the Settlement Amount will become immediately due and payable, plus accrued interest at a rate of 18% per annum, commencing from the date of default.

The Company determined that approximately $1.1 million dollars of the Settlement Amount was due within a year, and this amount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Settlement Amount that was due after a year was $2.2 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company made payments of $0.8  million as of June 30, 2021.

15

During the three and six months ended June 30, 2021, the Company recorded interest expense of $0.1 million and $0.2 million, respectively, in the consolidated statements of operations.

Contingencies

In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. The Company provides disclosures for material contingencies when there is a reasonable possibility that a loss or an additional loss may be incurred. In assessing whether a loss is a reasonable possibility, the Company may consider the following factors, among others: the nature of the litigation, claim or assessment, available information, opinions or views of legal counsel and other advisors, and the experience gained from similar cases. As of June 30,December 31, 2021, the Company was involved in the following material legal proceedings described below.

ThermoLife Internationalbelow:

 

In January 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to the Company, filed a complaint against the Company in Arizona state court. ThermoLife alleged that the Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. The court held a bench trial on the issue of damages in October 2019, and on December 4, 2019, the court entered judgment in favor of ThermoLife and against the Company in the amount of $1.6 million, comprised of $0.9 million in damages, interest in the amount of $0.3 million and attorneys’ fees and costs in the amount of $0.4 million. The Company recorded $1.6 million in accrued expenses in 2018. As of June 30, 2021, the total amount accrued, including interest, was $1.8 million. The Company has filed an appeal and posted bonds in the total amount of $0.6 million in order to stay execution on the judgment pending appeal. Of the $0.6 million, $0.25 million (including fees) was paid by Mr. Drexler on behalf of the Company. See “Note 8. Debt” for additional information. The balance of $0.35 million was secured by a personal guaranty from Mr. Drexler, while the associated annual fee of $12,500 has been paid by the Company. On April 27, 2021, the appellate court issued a decision largely affirming the trial court judgement, except vacating the judgement’s $0.3 million prejudgment interest award and remanding for a recalculation of prejudgment interest. On May 18, 2021, ThermoLife filed a motion asking the trial court to increase the Company’s appeal bond to the full amount of the judgment, or $1.8 million, which the Court denied on June 2, 2021.

For both the three months ended June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $22,000 and for both the six months ended June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $44,000.

The Company intends to vigorously continue pursuing its defenses. On June 25, 2021, the Company filed a petition for review in the Arizona Supreme Court requesting that the Court accept review of the appeal affirming the judgment against the Company. ThermoLife opposed the petition for review on July 26, 2021. The Arizona Supreme Court has not yet ruled on the Company’s petition for review.

White Winston Select Asset Fund Series MP-18, LLC et al., v.v MusclePharm Corp., et al., (Nev. Dist. Ct.; Cal. Superior Court; Colorado Dist. Ct.; Mass. Super. Ct.)

On August 21, 2018, White Winston Select Asset Fund Series MP-18, LLC and White Winston Select Asset Fund, LLC (together “White Winston”) initiated a derivative action against the Company and its directors (the “director defendants”). White Winston alleges that the director defendants breached their fiduciary duties by improperly approving the refinancing of three promissory notes issued by the Company to Mr. Drexler (the “Amended Note”) in exchange for $18.0 million in loans. White Winston alleges that this refinancing improperly diluted their economic and voting power and constituted an improper distribution in violation of Nevada law. In its complaint, White Winston sought the appointment of a receiver over the Company, a permanent injunction against the exercise of Mr. Drexler’s conversion right under the Amended Note, and other unspecified monetary damages. On September 13, 2018, White Winston filed an amended complaint, which added a former executive of the Company, as a plaintiff (together with White Winston, the “White Winston Plaintiffs”). On December 9, 2019, the White Winston Plaintiffs filed a Second Amended Complaint, in which they added allegations relating to the resignation of the Company’s auditor, Plante & Moran PLLC (“Plante Moran”). the Company has moved to dismiss the Second Amended Complaint. That motion has not yet been fully briefed.

 

16

Along with its complaint, White Winston also filed a motion for a temporary restraining order (“TRO”) and preliminary injunction enjoining the exercise of Mr. Drexler’s conversion right under the Amended Note. On August 23, 2018, the Nevada district court issued an ex parte TRO. On September 14, 2018, the court let the TRO expire and denied White Winston’s request for a preliminary injunction, finding, among other things, that White Winston did not show a likelihood of success on the merits of the underlying action and failed to establish irreparable harm. Following the court’s decision, the Company filed a motion seeking to recoup the legal fees and costs it incurred in responding to the preliminary injunction motion. On October 31, 2019, the court awarded the Company $56,000 in fees and costs.

 

Due to the uncertainty associated with determining our liability, if any, and due to our inability to ascertain with any reasonable degree of likelihood, as of the date of this report, the outcome of the trial, the Company has not recorded an estimate for its potential liability.

 

-17-

On June 17, 2019, White Winston moved for the appointment of a temporary receiver over the Company, citing Plante Moran’s resignation. The court granted White Winston’s request to hold an evidentiary hearing on the motion, but subsequently stayed the action pending the parties’ attempts to resolve their dispute. Although the parties have been unable to reach a resolution, the litigation has not yet resumed. On July 30, 2019, White Winston filed an action in the Superior Court of the State of California in and for the County of Los Angeles, seeking access to the Company’s books and records and requesting the appointment of an independent auditor for the company.Company. On February 25, 2021, the court ordered the Company to produce certain documents, denied White Winston’s request for an auditor, and ordered the Company to pay a $1,500 penalty. On July 20, 2021 the California court awarded White Winston $92,94293,000 in attorneys’ fees and cost relating to the books-and-records action. The Company paid the amounts due on July 30, 2021, and on August 4, 2021 White Winston submitted a filing acknowledging that the California court’s judgment has been fully satisfied.

 

The Company and its Chief Executive Officer have been named as defendants in a new lawsuit filed on February 8, 2022 by White Winston Select Asset Funds, LLC and White Winston Select Asset Fund Series Fund MP-18, LLC (collectively, “White Winston”) in the Superior Court of Suffolk County Massachusetts. White Winston is bringing claims alleging unfair trade practices, abuse of process, malicious prosecution, breach of duty of loyalty and, in the alternative, for breach of the settlement agreement relating to the prior action filed by White Winston in Nevada. The Company has not yet responded to complaint and at this time cannot reasonably estimate any loss that may arise from this matter.

IRS AuditBakery Barn, LLC v. MusclePharm Corporation

On April 6, 2016, the Internal Revenue ServiceJanuary 24, 2022, Bakery Barn (“IRS”Bakery Barn”) selected our 2014 Federal Income Tax Return for audit. As a result of the audit, the IRS proposed certain adjustments with respect to the tax reporting of our former executives’ 2014 restricted stock grants. Due to the Company’s current and historical loss position, the proposed adjustments would have no material impact on the Company’s Federal income tax. On October 5, 2016, the IRS commenced an audit of our employment and withholding tax liability for 2014. The IRS contended that thefiled suit against Company inaccurately reported the value of the restricted stock grants and improperly failed to provide for employment taxes and Federal tax withholding on these grants. In addition, the IRS proposed certain penalties associated with the Company’s filings. On April 4, 2017, thein Allegheny County, Pennsylvania court. Company received a “30-day letter” from the IRS asserting back taxes and penalties of approximately $5.3 million, of which $4.4 million related to withholding taxes, specifically, income withholding and Social Security taxes, and $0.9 million related to penalties. Additionally, the IRS assertedComplaint on February 16, 2022. Bakery Barn alleges that the Company owes information reporting penaltiesBakery Barn over $1.9 million dollars for breach of approximatelycontract. Parties operated on an open account basis with payment terms established by mutual verbal agreement, custom and usage. Beginning in late 2020, Bakery Barn resumed production for Company and operated under a verbal agreement until August 2021. Bakery Barn contends that Company is required to reimburse Bakery Barn for foil wraps ordered by Bakery Barn in the amount of $2.077,800 million., specific ingredients totaling $42,400, and products manufactured under purchase order Invoice no. 59192 delivered to Company in the amount of $1,816,017.

 

On February 24, 2022, Flaherty Fardo Rogel & Amick, LLC (“Company Counsel”) filed a Praecipe for Appearance on behalf of the Company. On February 28, 2022, Company Counsel filed Preliminary Objections to Complaint and Brief In Support Thereof. Bakery Barn filed an Amended Complaint in Civil Action on March 14, 2022. Company Counsel is in the process of filing Preliminary Objections to this Amended Complaint. The Company’s counsel submittedCompany intends to continue to vigorously litigate the matter.

Bar Bakers, LLC v. CFC/Flavor Producers, LLC. Vs MusclePharm

On March 18, 2022, the Company retained Barnes & Thornburg to represent it in connection with a formal protestCross-Complaint filed in the Superior Court of California, County of Orange, Case No. 30-2019-01073098-CU-BC-CJC in the matter Bar Bakers LLC v. Creative Flavor Concepts, Inc. et al.. According to the IRS disputing on several grounds allpleadings, the matter arises from an agreement between the plaintiffs and defendants in which the plaintiff agreed to manufacturer energy bars and sell them to the defendants. The defendants then sold the energy bars to various retailers, including the Company. On May 29, 2019, the plaintiff sued the defendants alleging that the defendants were responsible for unpaid invoices – nine for bars manufactured and delivered to the Company and one invoice for raw materials. According to the pleadings, the unpaid invoices total $885,163.72. The invoice for the raw materials is allegedly $4,658,593.02. On January 31, 2022, one of the proposed adjustmentsdefendants, Flavor Producers LLC, filed and penaltiesserved a cross claim against the Company alleging that it was partially responsible for any damages that may befall on it. Specifically, Flavor Producers is asking the Court to award it $389,989.60 in compensatory damages. On March 25, 2022, the Company filed an answer to that cross claim denying the factual allegations and Flavor Producers’ assertion that it is entitled to any damages, including but not limited to, compensatory damages.

ThermoLife International

In January 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to the Company, filed a complaint against the Company in Arizona state court. ThermoLife alleged that the Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. The court held a bench trial on the Company’s behalf,issue of damages in October 2019, and on December 4, 2019, the court entered judgment in favor of ThermoLife and against the Company pursued this matter vigorously throughin the IRSamount of $1.6 million, comprised of $0.9 million in damages, interest in the amount of $0.3 million and attorneys’ fees and costs in the amount of $0.4 million. The Company recorded $1.6 million in accrued expenses in 2018. The Company has filed an appeal process. An Appeals Conferenceand posted bonds in the total amount of $0.6 million in order to stay execution on the judgment pending appeal. Of the $0.6 million, $0.25 million (including fees) was held withpaid by Mr. Drexler on behalf of the IRS in Denver, Colorado on July 31, 2019. AtCompany. See “Note 7. Debt” for additional information. The balance of $0.35 million was secured by a personal guaranty from Mr. Drexler, the conference,associated fees of $12,500 and $2,500 have been paid by the Company made substantial arguments challengingCompany. On April 27, 2021, the IRS’s claimsappellate court issued a decision largely affirming the trial court judgement, except vacating the judgement’s $0.3 million prejudgment interest award and remanding for employment taxes and penalties.a recalculation of prejudgment interest. On December 16, 2019,May 18, 2021, ThermoLife filed a further Appeals Conference was held withmotion asking the IRS by telephone. At the telephone conference, the Appeals Officer confirmed that he agreed withtrial court to increase the Company’s argument thatappeal bond to the failure to deposit penalties should be conceded byfull amount of the IRS. The failure to deposit penalties total aboutjudgment, or $2 million. Thus, with this concession, the IRS’s claims have been reduced from approximately $7.31.9 million, to about $5.3 million.which the Court denied on June 2, 2021.

 

17-18-
 

As of March 31, 2022, the total amount accrued, including interest, was $1.9 million. For the three months ended March 31, 2022 and 2021, interest expense recognized on the awarded damages was $0.022 million and $0.022 million, respectfully.

On May 4, 2022, the Arizona Supreme Court denied the Company’s petition for review of the decision of the appellate court and granted ThermoLife’s request for attorney’s fees.

Settlements

Manchester City Football Group

 

The remaining issue involvedCompany was engaged in a dispute with City Football Group Limited (“CFG”), the fair market valueowner of restricted stock units the Company granted to certain former officers (the “Former Officers”) ofManchester City Football Group, concerning amounts allegedly owed by the Company under Internal Revenue Code § 83. Thea sponsorship agreement with CFG (the “Sponsorship Agreement”). In August 2016, CFG commenced arbitration in the United Kingdom against the Company, andseeking approximately $8.3 million for the IRS disagreed as to the valueCompany’s purported breach of the restricted stock onSponsorship Agreement.

On July 28, 2017, the dateCompany approved a Settlement Agreement (the “CFG Settlement Agreement”) with CFG effective July 7, 2017. The CFG Settlement Agreement represents a full and final settlement of all litigation between the parties. Under the terms of the grants, i.e., October 1, 2014.agreement, the Company agreed to pay CFG a sum of $3 million, which was recorded as accrued expenses in 2017. The settlement consists of a $1.0 million payment that was advanced by a related party on July 7, 2017, a $1.0 million installment paid on July 7, 2018 and a subsequent $1.0 million installment payment to paid by July 7, 2019. Of this amount, the Company has remitted $0.3 million.

During the three months ended March 31, 2022 and 2021, the IRS exchanged expert valuation reports onCompany recorded a charge of $0.018 million and $0.018 million, respectively. This charge, representing imputed interest, is included in “Interest expense” in the fair market valueCompany’s consolidated statements of the stock and had extensive negotiations on this issue. The IRS also made parallel claims regarding the restricted stock unitsoperations.

Nutrablend Matter

On February 27, 2020, Nutrablend, a manufacturer of MusclePharm products, filed an action against the Former Officers of the Company. The IRS asserted that the Former Officers received ordinary income from the stock grants, and that they owe additional personal income taxes based on the fair market value of the stock. The Former Officers’ cases, unlike the Company’s case, are pending beforeCompany in the United States Tax Court. InDistrict Court for the Tax Court litigation, the Former Officers are challenging the IRS’s determinations regarding the fair market valueEastern District of the restricted stock grants on October 1, 2014. The Former Officers have separate counsel from the Company. The same IRS Appeals Officer and Revenue Agents assignedCalifornia, claiming approximately $3.1 million in allegedly unpaid invoices. These invoices relate to the Company’s case are also involved in the casesthird and fourth quarter of 2019, and a liability has been recorded for the Former Officers. Throughoutrelated periods.

On September 25, 2020, the proceedings, parties successfully mediated the case to a settlement (the “Nutrablend Agreement”) and the Company has arguedagreed to the IRS that it is the Former Officers who are directly(i) pay approximately $3.1 million (“Owed Amount”) in monthly payments (“Monthly Payments”) from September 1, 2020 through June 30, 2023 and principally liable for the amount of any tax due, and not the Company.(ii) issue monthly purchase orders (“Purchase Orders”) at minimum amounts accepted by Nutrablend.

 

The Former Officers cases were scheduled for trialCompany agreed to issue Purchase Orders in Tax Courta combined total amount of at least (i) $1.5 million from September 1, 2020 through November 30, 2020; (ii) $1.8 million from December 1, 2020 through February 28, 2021; (iii) $2.1 million from March 31, 2021 through May 31, 2021; (iv) $2.1 million from June 1, 2021 through August 31, 2021; and (v) $1.4 million from September 1, 2021 through October 30, 2021. Beginning on March 9, 2020. The trialNovember 1, 2021, the Company will be required to issue monthly Purchase Orders to Nutrablend in a minimum amount of $0.7 million until the Owed Amount is paid in full to Nutrablend. In the event that the Company pays the Owed Amount in full before September 1, 2021, it’s entitled to a rebate on all completed Purchase Orders. Further, once the monthly payments, and any additional payments that the Company has made on the Owed Amount, reduce the outstanding balance of the cases was continued byOwed Amount to below $2.0 million, the Court on February 4, 2020. The basisCompany is eligible for the continuance was that the IRS and the Former Officers had made progress towardan extension of a settlementline of the valuation issue involving the grantscredit from Nutrablend in an amount of the restricted stock. The Tax Court ordered the Former Officersup to file status reports regarding progress of their settlement negotiations with the IRS on or before February 28, 2021. The IRS and the Former Officers filed status reports with the Tax Court on February 26, 2021. After receiving the status reports, the Tax Court issued an order directing the parties to file further status reports on or before July 9, 2021. The Tax Court has not set a trial dates in the cases of the Former Officers.$3.0 million.

 

On June 2,July 7, 2021, the IRS confirmedCompany commenced an action against Nutrablend in the Central District of California, seeking (i) a declaration that the Nutrablend Agreement purchase order provisions have been terminated due to Nutrablend’s failure to provide the Company with reasonable assurances of its ability to fulfill its purchase orders; (ii) a declaration that the statutes of limitations for the assessment and collection of employment tax and corporation income tax against the Company expired on December 15, 2020, without any assessments of tax or penalties. The IRS has told the Company that the employment tax and corporation income tax cases against the Company have been closed with finality, andapproximately $2.0 million in purchase orders that the Company has no liability for employment taxplaced in July and corporation income tax for 2014.August 2020 were intended to and do count towards the minimums set forth in the Nutrablend Agreement; and (iii) damages based on Nutrablend’s failure to fulfill purchase orders. The case is ongoing.

 

As of March 31, 2022, the Company determined that approximately $0.998 million of the owed amount was due within a year, and this amount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Owed Amount that was due after a year was $0.250 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company made payments of $0.303 million and $0.189 million during the three months ended March 31, 2022 and 2021, respectively.

-19-

On September 23, 2021, the Company entered into an Amendment to a Settlement Agreement that was originally entered into on September 25, 2020. Pursuant to the Amended Agreement, the Company is no longer obligated to issue Purchase Orders to Nutrablend as stated in the Settlement Agreement, which, as stated in the Form 8-K dated September 25, 2020, consisted of at least (i) $1.5 million from September 1, 2020 through November 30, 2020; (ii) $1.8 million from December 1, 2020 through February 28, 2021; (iii) $2.0 million from March 1, 2021 through May 31, 2021; (iv) $2.1 million from June 1, 2021 through August 22, 2018, Richard Estalella31, 2021; and (v) $1.4 million from September 1, 2021 through October 30, 2021. The Monthly Payments provision of the Settlement Agreement remains unchanged.

4Excelsior Matter

On March 18, 2019, Excelsior Nutrition, Inc. (“4Excelsior”), a manufacturer of MusclePharm products, filed an action against us and two other defendantsthe Company in the Colorado DistrictSuperior Court of the State of California for the County of Denver, seekingLos Angeles, claiming approximately $6.2 million in damages arising outrelating to allegedly unpaid invoices, as well as approximately $7.8 million in consequential damages.

On December 16, 2020, the Company and 4Excelsior entered into a Settlement Agreement and Mutual Release (“the Agreement”), pursuant to which the parties resolved and settled the civil action pending in the Superior Court of the IRS’s assertionState of tax liabilityCalifornia for the County of Los Angeles (the “Litigation”). The parties agreed to a mutual general release of claims and penalties relating to jointly file within 10 business days of the 2014 restricted stock grants. We have answered Estalella’s complaint,effective date of the Agreement a stipulation and proposed order of dismissal, dismissing with prejudice all claims and counterclaims asserted counterclaims against Estalella for his failure to ensure that all withholding taxes were paid in connection with the 2014 restricted stock grants, and filed cross-claims against two valuation firms named in the action (as well as their principals) for failingLitigation. The Company agreed to properly valuepay $4.75 million (the “Settlement Amount”) in four monthly payments of $70,000, beginning January 5, 2021, and thereafter in monthly payments of $100,000 until the 2014 restricted stock grants for tax purposes. TrialSettlement Amount is fully paid. The Company may prepay all or any portion of the Settlement Amount at any time without penalty or premium. The Agreement provides that, in the matter has been scheduled for February 7, 2022. There are no amountsevent of a Default (as defined in the Agreement) by the Company, the entire outstanding balance of the Settlement Amount will become immediately due and payable, plus accrued related tointerest at a rate of 18% per annum, commencing from the date of default.

The Company determined that approximately $1.1 million of the Settlement Amount was due within a year, and this matteramount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Settlement Amount that was due after a year was $1.6 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company will continue to vigorously litigatemade payments of $0.3 million and $0.2 million during the matter.three months ended March 31, 2022 and 2021, respectively.

The table below summarizes accrued expenses and interest expense incurred in for the three months ended March 31, 2022 and 2021 (in thousands):

Schedule of Accrued Expenses and Interest Expense

Cases 

Accrued Amount as of

March 31, 2022

  

Accrued Amount as of

December 31, 2021

  

Interest Expense for Period Ending

March 31, 2022

  

Interest Expense for Period Ending

March 31, 2021

 
Manchester City Football Group $730  $730  $(18) $(18)
Nutrablend Matter  1,248   2,318   (55)  (64)
4Excelsior Matter  2,715   3,597   (77)  (98)
ThermoLife International  1,364   1,364   (22)  (22)
Total $6,057  $8,009  $(172) $(202)

Note 10.9. Stock-Based Compensation

 

Restricted StockThe Company’s stock-based compensation for the three months ended March 31, 2022 and 2021 consisted primarily of stock option awards, and there was no activity other than vesting for the three months ended March 31, 2022.

 

For the three and six months ended June 30, 2021, the Company granted 25,000 restricted stock awards. The fair value of this grant is approximately $29,000, which is being expensed on a straight-line basis over two years.

There were 0 restricted stock awards granted during the three months and six months ended June 30, 2020.

For the three and six months ended June 30, 2021,March 31, 2022, the Company recorded approximately $0.00.4 million of stock-based compensation expense related to restricted stock.

For the three and six months ended June 30, 2020, thestock options. The Company recorded $0.1 and $0.2 million, respectively, ofdid not record stock-based compensation expense related to restricted stock.for the three months ended March 31, 2021.

 

18-20-
 

Transaction Equity Bonus

On April 5, 2021, with the appointment of the Company’s President and Chief Financial Officer, the Company granted an award where upon the occurrence of a sale of the Company, the President and Chief Financial Officer will receive 2% of the fully diluted equity of the Company. The grant will vest upon the one-year anniversary and if a sale transaction has not occurred by the two-year anniversary, then the President and Chief Financial Officer shall have the option to convert the transaction equity bonus into common shares. The fair value of this grant is approximately $1.0 million, which is being expensed on a straight-line basis over one-year.

For the three and six months ended June 30, 2021, the Company recorded $0.2 million of stock-based compensation expense related to transaction awards.

For the three and six months ended June 30, 2020, the Company recorded 0 expense related to transaction awards.

Stock Options

On May 12, 2021, the Company entered into an Agreement (the “Agreement”) with Joseph Cannata (“Cannata”), pursuant to which the Company has engaged Cannata on a non-exclusive basis to assist with the growth of the Company’s energy beverage product line.

In connection with entry into the Agreement, the Company issued to Cannata an option to purchase 1,673,994 shares of the Company’s common stock at a price per share of $1.12. The option has an exercise term of 10 years (subject to potential acceleration upon a sale of the Company) and will vest in two equal tranches upon the achievement of certain net revenue milestones related to the Company’s energy beverage products with the determination in the second quarter of 2021 that it is probable the performance criteria related to the grants will be achieved. The estimated fair value of this grant is $1.9 million and was determined by using the Black-Scholes valuation model with a term of 7.5 years; annual volatility rate of 205%; discount rate of 1.34%; and 0% for dividend rate. The fair value of performance-based restricted stock awards are recognized over the derived requisite vesting period beginning in the period in which they are deemed probable to vest.

For the three and six months ended June 30, 2021, the Company recorded approximately $60,000 of stock-based compensation expense related to stock options.

For the three and six months ended June 30, 2020, the Company recorded 0 expense related to stock options.

Note 11.10. Net LossIncome (Loss) per Share

 

The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share for the years presented (in thousands, except share and per share data):

Schedule of Basic and Diluted Net Income (loss) Per Share

         
  For the Three Months Ended March 31, 
  2022  2021 
Net Income (loss) $(6,301) $94 
Weighted average common shares used in computing net income (loss) per share, basic  33,386,200   33,119,549 
Potentially diluted securities  --   12,373,071 
Weighted average common shares used in computing net income (loss) per share, diluted  33,386,200   45,492,620 
Net income (loss) per share, basic $(0.19) $0.00 
Net income (loss) per share, diluted $(0.19) $0.00 

Basic net lossincome (loss) per share is computed by dividing net lossincome (loss) for the period by the weighted average number of shares of common stock outstanding during each period.

 

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data):

Schedule of Basic and Diluted Net Income (loss) Per Share

                 
  

For the Three Months

Ended June 30,

  

For the Six Months

Ended June 30,

 
  2021  2020  2021  2020 
Net loss $(2,251) $(253) $(2,157) $(313)
Weighted average common shares used in computing net loss per share, basic and diluted  33,386,200   32,764,553   33,131,087   32,612,956 
Net loss per share, basic and diluted $(0.07) $(0.01) $(0.07) $(0.01)

19

Diluted net lossincome (loss) per share is computed by dividing net lossincome (loss) for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding potentially dilutive securities, and the if-converted method to assess the dilutive effect of the convertible notes.

 

There was noAs of March 31, 2022, there were fully vested stock options of 1,651,884 that would have been dilutive effect for the outstanding awards for the three and six months ended June 30, 2021 and 2020, as the Company reported net loss for all periods presented. However, ifhad the Company had net income for the three and six months ended June 30, 2021, the potentially dilutive securities included in earnings per share computation would have been 12,544,774. If the Company had net income for the three and six months ended June 30, 2020, the potentially dilutive securities included in earnings per share computation would have been 2,663,715.income.

 

Total outstanding potentially dilutiveThe following securities were comprisedexcluded from the computations of the following:diluted net income (loss) per share, for the three months ended March 31, 2022 and 2021 as the effect of the securities would be anti-dilutive:

 Schedule of Outstanding Potentially Dilutive Securities

      
 As of June 30,  As of March 31, 
 2021  2020  2022  2021 
Stock options  171,703   171,703   5,399,441   171,703 
Warrants     1,289,378   18,463,511   - 
Unvested restricted stock     270,660 
Convertible notes  12,373,071   931,974   16,473,549   12,373,071 
Total common stock equivalents  12,544,774   2,663,715   40,336,501   12,544,774 

 

The average exercise price of the stock options and warrants as of March 31, 2022 is $0.77.

Note 12. 11. Income Taxes

 

The Company recorded aCompany’s tax provision of $7,000and $22,000 expense for the three months ended June 30,March 31, 2022 and 2021 and 2020, respectively, and $7,000and $44,000for the six months ended June 30, 2021 and 2020, respectively.was zero.

 

Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

 

Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of June 30, 2021.March 31, 2022.

-21-

 

Note 13.12. Segments, GeographicalSegment Information and Geographic Data

 

TheHistorically, the Company’s chief operating decision maker reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. As such, the Company currently has had a single reporting segment and operating unit structure. In addition, substantially all long-livedDuring the third quarter of 2021, the Company introduced a functional energy beverages line under the MusclePharm and FitMiss brands, at which time, the CODM commenced reviewing financial information on a disaggregated basis with the functional energy drink business separate from base business of protein products. During 2021, revenues for the functional energy drink segment were not material, but it is anticipated to become a more significant segment of the Company’s business going forward. (All amounts below are in thousands):

Schedule of Significant Segment Business Going Forward

  2022  2021 
  Three Months Ended March 31, 
  2022  2021 
Revenue, net        
Protein products $12,000  $13,121 
Energy drinks  1,101    
Total revenue, net $13,101  $13,121 

Schedule of Business Revenue and Profits

  Three Months Ended March 31, 2022 
  Revenue  Cost of Revenue  Gross Profit 
Protein products $12,000  $10,875  $1,125 
Energy drinks  1,101   717   384 
Total $13,101  $11,592  $1,509 

As the Company’s products are made through contract manufacturers’, there were no capital expenditures related to either segment during the three months ended March 31, 2022 and 2021. Energy segment assets are attributable to operations in the U.S. for both periods presented.were not material as of March 31, 2022.

 

20

All of the Company’s assets are located in the United States.

Geographic Information:

 

Revenue, netclassified by geographythe major geographic areas in which our customers are located is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands):as follows:

Schedule of Revenue, Major Geographical Areas

  2022  2021 
  Three Months Ended March 31, 
  2022  2021 
United States  94%  71%
Other Countries  6%  29%
Total revenue  100%  100%

No other country accounted for more than 5% of revenue during the three months ended March 31, 2022 and 2021. Geographically, sales to other countries are diverse – spanning every continent except Antarctica.

 Schedule of Revenue, Net by Geographic Area

                 2022  2021 
 

For the Three Months

Ended June 30,

  

For the Six Months

Ended June 30,

  Three Months Ended March 31, 
 2021  2020  2021  2020  2022  2021 
Revenue, net:                
Revenue, net        
Protein products        
United States $9,050  $13,514  $18,562  $25,361  $11,297  $9,274 
International  5,858   3,479   9,467   7,863   703   3,847 
Total Protein Products $12,000  $13,121 
        
Energy drinks        
United States  1,070   - 
International  31   - 
Total energy drinks $1,101  $- 
Total revenue, net $14,908  $16,993  $28,029  $33,224  $13,101  $13,121 

 

The MusclePharm brands are marketed across major global retail distribution channels. Below is a table of revenue, net by our major distribution channel (in thousands):

Schedule of Revenue, Net by Major Distribution Channel

  For the Three Months Ended June 30, 
  2021  % of
Total
  2020  % of
Total
 
Distribution Channel                
Specialty $9,983   67% $8,933   53%
International  1,775   12%  3,479   20%
FDM  3,150   21%  4,581   27%
Total $14,908   100% $16,993   100%

  For the Six Months Ended June 30, 
  2021  % of
Total
  2020  % of
Total
 
Distribution Channel                
Specialty $17,055   61% $16,969   51%
International  6,148   22%  7,863   24%
FDM  4,826   17%  8,392   25%
Total $28,029   100% $33,224   100%

Note 14. Subsequent Events

Related-Party Refinanced Convertible Note

On August 13, 2021 the Company and Ryan Drexler agreed to extend the November 2020 Convertible Note through July 14, 2022. The amendment did not change any terms of the agreement other than the maturity date.

Related Party Secured Revolving Promissory Note

 

On August 13, 2021, the Company issued to Ryan Drexler (the “Holder”) a convertible secured promissory note (the “August 2021 Convertible Note”) in the original principal amount of $2,457,549.

The August 2021 Convertible Note bears interest at the rate of 12% per annum. Interest payments are due on the last day of each calendar quarter. At the Company’s option (as determined by its independent directors), the Company may repay up to one sixth of any interest payment by either adding such amount to the principal amount of the August 2021 Convertible Note or by converting such interest amount into an equivalent amount of the Company’s common stock, $0.001 par value per share (the “Common Stock”). Any interest not paid when due shall be capitalized and added to the principal amount of the August 2021 Convertible Note and bear interest on the applicable interest payment date along with all other unpaid principal, capitalized interest, and other capitalized obligations. Both the principal and any accrued but unpaid interest under the August 2021 Convertible Note will be due on July 14, 2022, unless converted or repaid earlier.

The Holder may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price equal to the closing price of the common stock on October 15, 2021. The Company may prepay the August 2021 Convertible Note by giving the Holder between 15 and 60 days’ notice depending upon the specific circumstances, subject to the Holder’s conversion right.

The August 2021 Convertible Note contains customary events of default, including, among others, the failure by the Company to make a payment of principal or interest when due. Following an event of default, at the option of the Holder and upon written notice to the Company, or automatically under certain circumstances, all outstanding principal and accrued interest will become due and payable. The August 2021 Convertible Note also contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the August 2021 Convertible Note. The August 2021 Convertible Note is subordinated to certain other indebtedness of the Company.

Secured Borrowing Arrangement

On July 26, 2021, Prestige advanced the Company $1 million with a six month term and a 15% interest rate. In addition, there was an accommodation fee equal to 1% of the amount advanced plus 18,750 stock options.

21-22-
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

TheYou should read the following discussion and analysis of our financial condition and results of operations should be read in conjunctiontogether with and our consolidated financial statements and the related notes includedappearing elsewhere in this Quarterly Report on Form 10-Q (the “Form 10-Q”),10-Q. In addition to historical information, this discussion and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”), as filed with the Securities and Exchange Commission on March 29, 2021. This discussionanalysis contains forward-looking statements that involve risks, uncertainties and uncertainties.assumptions. Our actual results couldmay differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section entitledtitled “Risk Factors” included elsewherein our Annual Report on Form 10-K as amended for the fiscal year ended December 31, 2021 as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this Form 10-Q. Except asreport are in U.S. dollars, unless otherwise indicated herein, the terms “MusclePharm,” “Company,” “we,” “our” and “us” refer to MusclePharm Corporation and its subsidiaries.noted.

 

Overview

 

MusclePharm is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded sports nutrition products and nutritional supplements. We offer a broad range of performance powders, capsules, tablets, gels and on-the-go ready to eat snacks that satisfy the needs of enthusiasts and professionals alike. Our portfolio of recognized brands, MusclePharm and FitMiss, is marketed and sold in more thanto over 100 countries globally.

 

Our offerings are clinically developed through a six-stage research process, and all of our manufactured products are rigorously vetted for banned substances by the leading quality assurance program, Informed-Choice. While we initially drove growth in the Specialty retail channel, in recent years we have expanded our focus to drive sales and retailer growth across leading e-commerce, Food Drug & Mass (“FDM”), Specialty and Club retailInternational channels. Our primary distribution channels are Specialty, International and FDM.

 

  For the Months Ended March 31, 
  2022  % of Total  2021  % of Total 
Distribution Channel                
Specialty $3,383   26% $6,795   52%
International $733   6%  3,847   29%
FDM $8,985   68% $2,479   19%
Total $13,101   100% $13,121   100%

COVID-19

Our consolidated financial statements are prepared using the accrual method of accounting in accordance with generally accepted accounting principles in the United States (“GAAP”) and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.

 

Our results of operations have beenare affected by economic conditions, including macroeconomic conditions and levels of business confidence. There continues to be significant volatility and economic uncertainty in many markets and the ongoing COVID-19 pandemic has increased that level of volatility and uncertainty and has created economic disruption. As COVID-19 infections have been reported throughoutWe are actively managing our business to respond to the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of the infection. Additionally, more restrictive proclamations and/or directives may be issuedimpact. There were no adjustments recorded in the future.financial statements that might result from the outcome of these uncertainties.

COVID-19

The ultimateworldwide spread of COVID-19, including the emergence of variants, has resulted, and may continue to result in a global slowdown of economic activity, which may decrease demand for a broad variety of goods and services, while also disrupting supply channels, sales channels and advertising and marketing activities for an unknown period of time until the COVID-19 pandemic is contained, or economic activity normalizes. With the current uncertainty in economic activity, the impact on our revenue and results of operations is likely to continue and the size and duration of the impact we are currently unable to accurately predict. The extent of the impact of the COVID-19 pandemic on the Company’s operations is unknownour operational and financial performance will depend on future developments,a variety of factors, including the duration and spread of COVID-19 and its variants, and its impact on our customers, contract manufacturers, vendors, industry and employees, all of which are highly uncertain at this time and cannot be predicted with confidence, including the durationaccurately predicted. See “Item 1.A Risk Factors” for further discussion of the COVID-19 outbreak, new information which may emerge concerning the severityadverse impacts of the COVID-19 pandemic and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expense.business.

22-23-
 

 

Factors Affecting Our Performance

As we continue to execute our growth strategy and focus on our core products, we believe that we can, over time, continue to improve our operating margins and expense structure. In addition, we have implemented plans focused on cost containment, customer profitability, product and pricing controls that we believe will improve our gross margin and reduce our losses.

We expect that our advertising and promotion expense will continue to decrease as we focus on reducing our expenses and shifting our promotional costs, in part, from general branding and product awareness to acquiring customers and driving sales from existing customers. We expect that our discounts and allowances will continue to decrease, both overall and as a percentage of revenue, as we further reduce certain discretionary promotional activity that does not result in a commensurate increase in revenues.

Results of Operations

 

Comparison of the Three Months Ended June 30, 2021March 31, 2022 to the Three Months Ended June 30, 2020 ($ in thousands):

  

For the Three Months Ended

June 30,

       
  2021  2020  $ Change  % Change 
Revenue, net $14,908  $16,993  $(2,085)  (12)%
Cost of revenue  12,728   12,009   719   6 
Gross profit  2,180   4,984   (2,804)  (56)
Operating expenses:                
Advertising and promotion  145   188   (43)  (23)
Salaries and benefits  1,181   1,774   (593)  (33)
Selling, general and administrative  2,115   1,807   306   17 
Professional fees  482   865   (383)  (44)
Total operating expenses  3,923   4,634   (713)  (15)
Income from operations  (1,743)  350   (2,091)  (597)
Other expense:                
Interest and other expense, net  (501)  (581)  80   (14)
Income (loss) before provision for income taxes  (2,244)  (231)  (2,011)  (871)
Provision for income taxes  7   22   (15)  (68)
Net income (loss) $(2,251) $(253) $(1,996)  (789)%

March 31, 2021:

Comparison of the Six Months Ended June 30, 2021 to the Six Months Ended June 30, 2020 ($ in thousands):

  

For the Six Months Ended

June 30,

     
  2021  2020  $ Change  % Change 
Revenue, net $28,029  $33,224  $(5,195)  (16)%
Cost of revenue  22,160   23,431   (1,271)  (5)
Gross profit  5,869   9,793   (3,924)  (40)
Operating expenses:                
Advertising and promotion  489   313   176   56 
Salaries and benefits  2,229   3,455   (1,226)  (35)
Selling, general and administrative  3,512   3,718   (208)   (6)
Professional fees  1,109   1,406   (297)  (21)
Total operating expenses  7,339   8,892   (1,555)  (21)
Income from operations  (1,470)  901   (2,369)  (263)
Other expense:                
Interest and other expense, net  (680)  (1,170)  490   (42)
Income (loss) before provision for income taxes  (2,148)  (269)  (1,879)  (699)
Provision for income taxes  7   44   (37)  (84)
Net income (loss) $(2,157) $(313) $(1,842)  (588)%

23

The following table presentssets forth certain financial information from our operating results asconsolidated statements of operations along with a percentage of net revenue net forand should be read in conjunction with the periods presented:consolidated financial statements and related notes (in thousands).

  

For the Three Months

Ended June 30,

  For the Six Months Ended
June 30,
 
  2021  2020  2021  2020 
Revenue, net  100%  100%  100%  100%
Cost of revenue  85   71   79   71 
Gross profit  15   29   21   29 
Operating expenses:                
Advertising and promotion  1   1   2   1 
Salaries and benefits  8   10   8   10 
Selling, general and administrative  14   11   13   11 
Professional fees  3   5   4   4 
Total operating expenses  26   27   26   26 
Gain (loss) from operations  (12)  2   (5)  3 
Other income (expense):                
Interest and other expense, net  (3)  (3)  (2)  (4)
Loss before provision for income taxes  (15)  (1)  (8)  (1)
Provision for income taxes            
Net loss  (15)%  (1)%  (8)%  (1)%
  For the Months Ended March 31, 
  2022  2021 
  Amount  % of Revenue  Amount  % of Revenue 
Revenue, net $13,101   100% $13,121   100%
Cost of revenue  11,592   88%  9,432   72%
Gross profit  1,509   12%  3,689   28%
Operating expenses:                
Selling and promotion  1,160   9%  1,149   9%
General and administration  2,829   22%  2,268   17%
Total operating expenses  3,989   30%  3,417   26%
Income (loss) from operations  (2,480)  -19%  272   2%
Other (expense) income:                
Gain on settlements  12   0%  200   2%
Interest expense  (3,821)  -29%  (510)  -4%
Other (expense) income, net  (12)  0%  132   1%
Income (loss) before provision for income taxes  (6,301)  -48%  94   1%
Net income (loss) $(6,301)  -48% $94   1%

Revenue, net

 

We derive our revenue through the sales of our various branded sports nutrition products, nutritional supplements.supplements and energy drinks. Revenue is recognized when control of a promised good is transferred to a customer in an amount that reflects the consideration that the Company expects to be entitled to in exchange for thatthe good. This usually occurs when finished goods are delivered to the Company’s customers or when finished goods are picked up by a customer or a customer’s carrier.

 

The MusclePharm brands are marketed across major global retail distribution channels. Below is a table ofNet revenue net by distribution channel (in thousands):

  For the Three Months Ended June 30, 
  2021  % of
Total
  2020  % of
Total
 
Distribution Channel                
Specialty $9,983   67% $8,933   53%
International  1,775   12%  3,479   20%
FDM  3,150   21%  4,581   27%
Total $14,908   100% $16,993   100%

  For the Six Months Ended June 30, 
  2021  % of
Total
  2020  % of
Total
 
Distribution Channel                
Specialty $17,055   61% $16,969   51%
International  6,148   22%  7,863   24%
FDM  4,826   17%  8,392   25%
Total $28,029   100% $33,224   100%

Revenue, net reflects the transaction prices for contracts, which includes productsgoods shipped at selling list prices reduced by variable consideration.discounts and sales allowances. We record discounts and sales incentivesallowances as a direct reduction of revenue for various discounts provided to our customers, consisting primarily of volume incentive rebates and promotional related credits. We accrue for sales discounts over the period they are earned. Sales discounts are a significant part of our marketing plan to our customers as they help drive increased sales and brand awareness with end users through promotions that we support through our distributors and re-sellers.

 

24-24-
 

 

Revenue,For the three months ended March 31, 2022, our net decreased $2.1revenues were approximately $13.1 million or 12%,compared to $14.9$13.1 million for the three months ended June 30,March 31, 2021, compareda decline of approximately $20,000 or 0%. Net revenue for the energy segment was up $1 million, primarily driven by volume, while net revenue for the protein products segment was down $1 million. During the three months ended March 31, 2022, the Company had three customers who individually accounted for 59%, 13% and 12% of our net revenue. During the three months ended March 31, 2021, the Company had three customers who individually accounted for 28%, 17% and 14% of our net revenue. During the 1st Quarter of 2022 the Company instituted a price increase with select customers, contributing to $17.0 million7.4 % of revenue for the three months ended June 30, 2020. Revenue, net for the three months ended June 30, 2021 decreased primarily due to industry wide supply shortages on components and protein, which delayed production of our products.March 31, 2022.

 

Discounts and sales allowances decreaseddeclined to approximately 11% of gross revenue, or $1.9$1.6 million, for the three months ended June 30, 2021, from 17%March 31, 2022, compared to approximately 15% of gross revenue, or $3.6$2.4 million, for the same period in 2020. The reduction in discounts as a percent of gross revenue was due to changes in customer mix and discretionary promotional activity.

During the three months ended June 30, 2021 and 2020, our largest customer accounted for approximately 55% and 43% of our revenue, net, respectively.

Revenue, net decreased $5.2 million, or 16%, to $28.0 million for the six months ended June 30, 2021, compared to $33.2 million for the six months ended June 30, 2020. Revenue, net for the six months ended June 30, 2021 decreased primarily due to industry wide supply shortages on components and protein, which delayed production of our products.

March 31, 2021. Discounts and sales allowances decreased to 11% of gross revenue, or $4.3 million, for the six months ended June 30, 2021, from 27% of gross revenue, or $7.6 million for the same period in 2020. The reduction in discounts as a percent of gross revenue was due to changes influctuate based on customer mix and changes in discretionary promotional activity. We continue to monitor our discounts and allowances, reducing where practical to continue to meet our gross margin expectation.

 

During the six months ended June 30, 2021 and 2020, our largest customer accounted for approximately 43% and 33% of our revenue, net, respectively.

Cost of Revenue and Gross Profit

 

Cost of revenue for MusclePharmour products is directly related to the production, manufacturing, and freight-in of the related products purchased from third party contractthird-party manufacturers. We primarily use contract manufacturers to drop ship products directly to our customers.

 

Our gross profit fluctuatesWe experienced cost increases for raw materials during the three months ended March 31, 2022 primarily due to several factors, including sales incentives,industry shortages in supply and consistent with market demand. Compared to the prior year, commodity protein costs have increased 90% negatively affecting our gross margin. We are taking steps to manage the increase and shortages by entering into agreements with additional protein brokers to diversify our protein sources, along with working with new product introductionsvendors to source other component such as tubs, trays and upgrades to existing product lines, changes in customer and product mixes, the mix of product demand, shipment volumes, our product costs, and pricing.bags.

 

Costs of revenue increased 6%, despite the decrease in sales volume, to $12.7 million for the three months ended June 30, 2021, compared to $12.0 million for the same period in 2020. This increase was due to increased commodity costs, specifically protein, the prices of whichWe have risen significantly year over year,focused on cost containment and improving gross margins by concentrating on customers with higher margins, reducing product discounts and promotional activity, along with increased freight costs. Gross profitreducing the number of SKU’s and negotiating improved pricing for the three months ended June 30, 2021 decreased 15% to $2.2 million, compared to $5.0 million for the same periodraw materials. With recent increases in 2020. Gross profit was 15% of revenue, net for the three months ended June 30, 2021 compared to 29% of revenue, net for the same period in 2020. Negatively impacting the gross profit percentage were higher commodity prices, specifically for proteinour gross margins have eroded and freight costs.will continue to be impacted.

 

CostsWe are focusing on growing the energy segment which contributed to two points of revenue decreased 5% to $22.2 million formargin in the sixthree months ended June 30, 2021, compared to $23.4 million for the same period in 2020. This decrease was due to lower sales volume along with increased commodity costs, specifically protein, prices of which have risen significantly year over year, along with increased freight costs. Gross profit for the six months ended June 30, 2021 decreased 21% to $5.9 million, compared to $9.8 million for the same period in 2020. Gross profit was 21% of revenue, net for the six months ended June 30, 2021 compared to 29% of revenue, net for the same period in 2020. Negatively impacting the gross profit percentage were higher commodity, specifically for protein and freight costs.

March 31, 2022.

25

 

Operating ExpensesSelling and promotion

 

Advertising and Promotion

Our advertisingselling and promotion expense consists primarily of expenses related to club demonstrations,freight-out, print and online advertising, trade showsclub demonstrations, and strategic partnerships with athletes and sports teams.stock-based compensation. Historically, advertising and promotions were a large part of both our growth strategy and brand awareness, in particular strategic partnerships with sports athletes and fitness enthusiasts throughand endorsements, licensing, and co-branding agreements. Additionally, we co-developed products with sports athletes and teams. In connection with our restructuring plan, we terminated the majoritymost of these contracts in a strategic shift away from such costly arrangements and moved toward more cost-effective programs, including digital advertising, ambassador programs and sampling/sampling promotional materials.

 

AdvertisingFor the three months ended March 31, 2022, our selling and promotion expense decreased 23%expenses were approximately $1.2 million compared to $0.1$1.1 million for the three months ended June 30,March 31, 2021, an increase of $11,000 or 1% of revenue, net compared to $0.2 million, or 1% of revenue, net for the same period in 2020.. The decrease for 2021 isincrease was primarily related to decreased marketing expenses.an increase in freight-out and stock-based compensation related to our Energy business and offset by decreases in Club Demonstrations. Freight out is up $77,000 or 11% and Stock based compensation is up $142,000 or 100%. Club demonstrations were down $222,000 or 75%. All other selling and promotion expenses represent an increase of $14,000.

 

-25-

Advertising and promotion expense increased 56% to $0.5 million for the six months ended June 30, 2021, or 2% of revenue, net compared to $0.3 million, or 1% of revenue, net for the same period in 2020. The increase for 2021 is related to increased demonstrations and sampling due to the launch of a new flavor for our performance powders with one of our largest customers during the first quarter of 2021.

Salaries and Benefits

Salaries and benefits consist primarily of salaries, bonuses, benefits, and stock-based compensation. Personnel costs are a significant component of our operating expenses.

Salaries and benefits decreased 16% to $1.2 million, or 7% of revenue, net for the three months ended June 30, 2021 compared to $1.8 million, or 10% of revenue, net for the same period in 2020 primarily due to a reduction in headcount as we have focused on reducing operating costs.

Salaries and benefits decreased 37% to $2.2 million, or 7% of revenue, net for the six months ended June 30, 2021 compared to $3.5 million, or 10% of revenue, net for the same period in 2020 primarily due to a reduction in headcount as we have focused on reducing operating costs.

Selling, General and Administrative

 

Our selling, general and administrative expenses consist primarily of salaries and benefits, professional fees, depreciation and amortization, research and development, information technology equipment and network costs, facilities related expenses, director’sdirectors’ fees, which include both cashlegal fees, accounting and audit fees, consulting fees, stock-based compensation, investor relations costs, insurance, rental expenses related to equipment leases, supplies, legal settlement costs,bad debt and other corporate expenses.

 

Selling,For the three months ended March 31, 2022, our general and administrative expenses increased 17% to $2.1were approximately $2.8 million or 14% of revenue, netcompared $2.3 million for the three months ended June 30,March 31, 2021, compared to $1.8 million, or 11%an increase of revenue, net for the same period in 2020 primarilyapproximately $561,000 or 25%. This was due to an increase in bad debt reserves, partially offset by reduction in board member compensation and office expensesprofessional fees associated with closure of headquartersaccounting fees, an increase in salaries and warehouses.

Selling, general and administrative expenses decreased 5% to $3.5 million, or 13% of revenue, net for six months ended June 30, 2021, compared to $3.7 million, or 11% of revenue, net for the same period in 2020 primarily due to a reduction in board member compensation and office expensesbenefits associated with closure of headquartersstock-based compensation and warehouses, partially offset by an increase in bad debt reserves.

expense, offset by a reduction in office and IT expenses. Professional Feesfees are up $213,000 or 41%, salaries and benefits are up $176,000 or 17%, and bad debt expense is up $344,000 or 3100% and office/IT expenses are down $96,000 or 39%. All other general and administrative expenses represent a decrease of $76,000.

 

Professional fees consist primarily of legal fees, accounting and audit fees, consulting fees, which includes both cash and stock-based compensation, and investor relations costs.

26

Professional fees decreased 44% to $0.5 million, or 3% of revenue, net for the three months ended June 30, 2021, compared to $0.9 million, or 5% of revenue, net for the same period in 2020 primarily due to the deceased costs in consulting fees.

Professional fees decreased 21% to $1.1 million, or 4% of revenue, net for the six months ended June 30, 2021, compared to $1.4 million, or 4% of revenue, net for the same period in 2020 primarily due to decreased consulting fees.

Interest and other expense, netGain on Settlements

 

For the three months ended June 30,March 31, 2022 and 2021, gain on settlements was $12,000 and 2020, “Interest and other expense, net” consisted of the following (in thousands):

  

For the

Three Months

Ended June 30,

  

For the

Six Months

Ended June 30,

 
  2021  2020  2021  2020 
             
Interest expense, related party $(147) $(76) $(282) $(152)
Interest expense, other  (235)  (175)  (443)  (332)
Interest expense, secured borrowing arrangement  (258)  (383)  (424)  (748)
Foreign currency transaction loss  34   16   32   (18)
Other  105   74   438   167 
Total interest and other expense, net $(501) $(544) $(679) $(1,083)

“Other” includes sublease income.$200,000 respectively.

 

NetInterest Expense

For the three months ended March 31, 2022, interest and other expense was approximately $3.8 million compared to $0.5 million for the three months ended June 30,March 31, 2021, decreased 14%, or $0.1 million, compared to the same period in 2020. The decrease is primarily related to reduced interest expense for secured borrowing arrangements, partially offset by an increase in interest expense for related party and other debt.of $3.3 million or 645%.

 

Net interest and otherInterest expense for the six months ended June 30, 2021 decreased 42%, or $0.4 million, compared to the same period in 2020. The decrease isincreased primarily due to reduced interestthe $3.2 million amortization of stock warrants associated with the issuance of the Senior Secured debt offering during the year ended December 31, 2021.

Other (Expense) Income, Net

For the three months ended March 31, 2022 and 2021, other expense for secured borrowing arrangements, partially offset by an increase in interest expense for related party andwas $12,000, compared to other debt.income of $132,000 respectively.

 

Provision for Income Taxes

 

ProvisionFor the three months ended March 31, 2022 and 2021, tax expense was zero. Our provision for income taxes consists primarily of federal and state income taxes in the U.S. and income taxes in foreign jurisdictions in which we conduct business. Due to uncertainty, as to the realization of benefits from our deferred tax assets, including net operating loss carry-forwards,carryforwards, research and development and other tax credits, we have a full valuation allowance reserved against such assets. We expect to maintain this full valuation allowance at least in the near term.

Liquidity and Capital Resources

 

The Company hasWe have incurred significant losses and experienced negative cash flows since inception. As of June 30, 2021, the CompanyMarch 31, 2022, we had cash of $1.0$0.5 million, a decline of $1.0$0.7 million from the December 31, 20202021 balance of $2.0$1.2 million. As of June 30, 2021,March 31, 2022, we had a working capital deficit of $22.8$36.3 million, a stockholders’ deficit of $26.3$38.1 million and an accumulated deficit of $194.8$211.8 million resulting from recurring losses from operations. As a result of our history of losses and financial condition, there is substantial doubt about our ability to continue as a going concern. For financial information concerning more recent periods, see our reports for such periods filed with the SEC.

 

27

TheOur ability to continue as a going concern is dependent upon us generating profitable operations in the future and/or obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. Management isWe are evaluating different strategies to obtain financing to fund our expenses and achieve a level of revenue adequate to support our current cost structure. Financing strategies may include, but are not limited to, private placementsissuances of capital stock, debt borrowings, partnerships and/or collaborations.

 

During the fourth quarter of 2019, the Company focused on cost containment and improving gross margins by focusing on customers with higher margins, reducing product discounts and promotional activity, along with reducing the number of SKU’s and negotiate pricing for raw materials. These steps improved gross margins in the fourth quarter of 2019 and this trend has continued through June 30, 2021. However, with the recent increases in commodity prices, the company’s gross margins have been impacted and will continue to be impacted unless commodity prices return the same levels that were seen in 2020.

During 2020, the Company experienced a slowdown in sales from retail customers, including our largest customer, which was partially offset by an increase in sales from our largest online customer. In addition, the Company negotiated lower cost of sold with its co-manufactures.

In 2021, the Company announced its entrance into the functional energy space with its partnership with a former Rockstar Energy executive. The Company plans to launch 3 new energy products in the summer of 2021.

The Company believes with the launch of its new energy products, reductions in operating costs and continued focus on gross profit and top line sales growth will allow it to ultimately achieve sustained profitability, however, the Company can give no assurances that this will occur. In addition, the cost to launch new energy products along with the recent increase in the cost of protein may have a material impact on the Company’s profitability, as well as the ability of our third-party manufacturers to meet our customers’ demands. Although, the Company believes entering the functional energy space will help to increase sales and gross margin, and reduce exposure to commodity prices, the Company can give no assurances that this will occur.

Management believes reductions in operating costs and continued focus on gross profit will allow us to ultimately achieve profitability, however, the Company can give no assurances that this will occur. To manage cash flow, we have entered into numerous financing arrangements outlined in “Note 8. Debt” to the Notes to Consolidated Financial Statements (unaudited) contained herein.

Our net consolidated cash flows are as follows (in thousands):

  

For the Six Months

Ended June 30,

 
  2021  2020 
Consolidated Statements of Cash Flows Data:        
Net cash (used in) provided by operating activities $(899) $1,191 
Net cash (used in) provided by investing activities  (3)  11 
Net cash used in financing activities  (85)  (1,521)
Net change in cash $(987) $(319)

Operating Activities

Our cash provided by operating activities is driven primarily by sales of our products and vendor provided credit. Our primary uses of cash from operating activities have been for inventory purchases, advertising and promotion expenses, personnel-related expenditures, manufacturing costs, professional fees, costs related to our facilities, and legal fees. Our cash flows provided by operating activities will continue to be affected principally by the results of operations and the extent to which we increase spending on personnel expenditures, sales and marketing activities, and our working capital requirements.

Cash used in operating activities decreased by $2.1 million for the period ended June 30, 2021 to $0.9 million compared to cash provided by operations of $1.2 million for 2020.

During the six months ended June 30, 2021, the primary change in net operating assets and liabilities was primarily the result of a net loss of $2.2 million, partially offset by non-cash items of amortization, bad debt expense and stock-based compensation, along with decreases in prepaid and other assets and increases in accounts payable and accrued liabilities.

28-26-
 

 

DuringWe have funded our operations from proceeds from the sixsale of equity and debt securities. We will require significant additional capital to make the investments we need to execute our longer-term business plan. Our ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to our existing shareholders and future debt securities may contain covenants that limit our operations or ability to enter into certain transactions.

We will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for our existing and new product candidates. If such funding is not available, or not available on terms acceptable to us, our current development plan and plans for expansion of our general and administrative infrastructure may be curtailed.

Cash Flows

A summary of our cash flows is as follows (in thousands):

  For the Months Ended March 31, 
  2022  2021 
Consolidated Statements of Cash Flows Data:      
Net cash (used in) provided by operating activities $(3,582) $98 
Net cash used in investing activities  -   (4)
Net cash provided by (used in) financing activities  2,893   (1,505)
Net change in cash $(689) $(1,411)

Net Cash Operating Activities

Our net cash used in operating activities was $3.6 million for the three months ended June 30, 2020, theMarch 31, 2022, compared to net cash provided by operating activities of $1.2$0.1 million primarily relates tofor the three months ended March 31, 2021. The primary drivers include a $6.1 million net loss, and an increase in accounts receivable, net of $0.3 million, offset by non-cash items of amortization, bad debt expense, and stock-based compensation, along with decreases in prepaid and other assets.$2.5 million.

 

Net Cash Investing Activities

 

DuringOur net cash used in investing activities for the sixthree months ended June 30, 2021,March 31, 2022, was zero compared to net cash used wasin investing activities of $0.004 million for the purchase of computer equipment. During the sixthree months ended June 30, 2020, we received $11,000 of proceeds from the disposal of property and equipment.March 31, 2021.

 

Net Cash Financing Activities

 

Cash used inOur net cash provided by financing activities for the sixthree months ended June 30, 2021March 31, 2022, was $0.1 million. During$2.9 million compared to net cash used by financing activities of $1.5 million for the sixthree months ended June 30, 2021 cash used in financing activities was for repayments on secured borrowing arrangement, offset by proceeds from line of credit.

Cash used in financing activities for the six months ended June 30, 2020 was $1.5 million. During the six months ended June 30, 2020 cash used in financing activities was for repayment of secured borrowing arrangements.

Indebtedness Agreements

For information regarding our indebtedness agreements, see “Note 8. Debt” to the Notes to Consolidated Financial Statements (unaudited) contained herein.

Contingencies

For information regarding contingencies, see “Note 9. Commitments and Contingencies” to the Notes to Consolidated Financial Statements (unaudited) contained herein.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of June 30,March 31, 2021.

 

Non-GAAP Adjusted EBITDA

 

In addition to disclosing financial results calculated in accordance with U.S. GAAP, this Quarterly Report on Form 10-Q discloses Adjusted EBITDA, which is net loss adjusted for items such as stock-based compensation, gain or loss(gain) on disposalsettlement of property and equipment, (gain) loss on settlements,accounts payable, interest and other expense, net, depreciation of property and equipment, amortization of intangible assets, provision for doubtful accounts and provision for income taxes.(gain) or loss on foreign currency.

 

Management uses Adjusted EBITDA as a supplement to U.S. GAAP measures to further evaluate period-to-period operating performance, as well as the Company’s ability to meet future working capital requirements. The exclusion of non-cash charges, including stock-based compensation gain on disposal of property and equipment, depreciation of property and equipment, amortization of intangible assets, provision for doubtful accounts and provision for income taxes, is useful in measuring the Company’s cash available for operations and performance of the Company. Management believes these non-U.S. GAAPthis non-GAAP measures will provide investors with important additional perspectives in evaluating the Company’s ongoing business performance.

 

-27-

The U.S. GAAP measure most directly comparable to Adjusted EBITDA is net income (loss). The non-GAAP financial measure of Adjusted EBITDA should not be considered as an alternative to net income (loss). Adjusted EBITDA is not a presentation made in accordance with U.S. GAAP and has important limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Because Adjusted EBITDA excludes some, but not all, items that affect net income (loss) and is defined differently by different companies, our definition of Adjusted EBITDA may not be comparable to similarly titled measures of other companies.

 

29

Set forth below are reconciliations of our reported U.S. GAAP net lossincome (loss) to Adjusted EBITDA (in thousands):

 

  

For the

Three Months ended

  

For the

Three Months

ended

  

For the

Six Months ended

  

For the

Six Months ended

 
  June 30, 2021  June 30, 2020  June 30, 2021  June 30, 2020 
             
Net Loss $(2,251) $(253) $(2,157) $(313)
                 
Non-GAAP adjustments:                
Stock-based compensation  308   79   308   179 
Gain on disposal of property and equipment           (11)
(Gain) loss on settlements  29      (171)   
Interest and other expense, net  606   618   1,118   1,248 
Depreciation and amortization of property and equipment  3   42   6   105 
Amortization of intangible assets  80   80   160   160 
Provision for doubtful accounts  338   110   327   121 
Provision for income taxes  7   22   7   44 
                 
Adjusted EBITDA $(880) $698  $(402) $1,533 
  For the Three Months Ended March 31, 
  2022  2021 
Net income (loss) (GAAP) $(6,301) $94 
Non-GAAP adjustments:        
Gain on settlements  (12)  (200)
Stock compensation expense  437   - 
Interest expense and other income  3,821   510 
Depreciation of Property and Equipment  1   3 
Amortization of Intangible Assets  35   80 
(Gain) loss from foreign currency  12   (11)
Adjusted EBITDA (non-GAAP) $(2,007) $476 

 

Critical Accounting Policies and Estimates

 

Our consolidated financial statements have been prepared in accordance with GAAP and form the basis for the following discussion and analysis on critical accounting policies and estimates. The preparation of the accompanying consolidated financial statements and related disclosures in conformity with U.S. GAAP and our discussion and analysis of our financial condition and operating results require our managementrequires us to make judgments,estimates and assumptions and estimates that affect the reported amounts reported in these consolidated financial statementsof assets, liabilities, revenues and accompanying notes. Management bases itsexpenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates and assumptions on a regular basis. We base our estimates on historical experience and on various other assumptions we believethat are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.liabilities that are not readily apparent from other sources. Actual results maycould differ from these estimates and suchthose differences could have a material effect on our business, financial condition and results of operations.

The preparation of our Financial Statements and the related disclosures in conformity with GAAP, requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our Financial Statements and accompanying notes. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies is integral to understanding our Financial Statements.

We describe our most significant accounting policies in “Note 2, Significant Accounting Policies” of our consolidated notes to our Financial Statements and found elsewhere in this Quarterly Report. These policies are considered critical because they may be material.result in fluctuations in our reported results from period to period due to the significant judgments, estimates, and assumptions about highly complex and inherently uncertain matters. In addition, the use of different judgments, assumptions, or estimates could have a material impact on our financial condition or results of operations. We evaluate our critical accounting estimates and judgments required by our policies on an ongoing basis and update them as appropriate based on changing conditions.

Revenue Recognition

 

Our critical accountingrevenue represents sales of finished goods inventory and is recognized when control of the promised goods is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods. The reserves for trade promotions and product discounts, including sales incentives, are established based on our best estimate of the amounts necessary to settle existing credits for products sold as of the balance sheet date.

-28-

All such costs are netted against sales. These costs include end-aisle or other in-store displays, contractual advertising fees and product discounts, and other customer specific promotional activity. We provide reimbursement to our customers for such amounts as credits against amounts owed. To determine the appropriate timing of recognition of consideration payable to a customer, all consideration that is payable to our customers is reflected in the transaction price at inception and reassessed routinely.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms and are recorded at the invoiced amount, net of any sales discounts and allowance for doubtful accounts, and do not typically bear interest. We assess the collectability of the accounts by taking into consideration the aging of accounts receivable, changes in customer credit worthiness, general market and economic conditions, and historical experience. Bad debt expenses are recorded as part of “General and administrative” expenses in the consolidated statements of operations. We reserve the receivable balance against the allowance when management determines a balance is uncollectible. We also review our customer discounts, and an accrual is made for discounts earned but not yet utilized at each period end.

Litigation Estimates and Accruals

In the normal course of business or otherwise, we may become involved in legal proceedings. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. We provide disclosures for material contingencies when there is a reasonable possibility that a loss or an additional loss may be incurred. In assessing whether a loss is a reasonable possibility, we may consider the following factors, among others: the nature of the litigation, claim or assessment, available information, opinions or views of legal counsel and other advisors, and the experience gained from similar cases.

Share-Based Payments and Stock-Based Compensation

Share-based compensation awards, including stock options and restricted stock awards, are detailedrecorded at estimated fair value on the applicable awards’ grant date, based on the estimated number of awards that are expected to vest. The grant date fair value is amortized on a straight-line basis over the time in Part I, Item 7which the awards are expected to vest, or immediately if no vesting is required. Share-based compensation awards issued to non-employees for services are also recorded at fair value on the grant date. The fair value of restricted stock awards is based on the fair value of the stock underlying the awards on the grant date as there is no exercise price.

The fair value of stock options is estimated using the Black-Scholes option-pricing model. The determination of the fair value of each stock award using this option-pricing model is affected by our Annual Reportassumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards and the expected term of the awards based on Form 10-K foran analysis of the year ended December 31, 2020.actual and projected employee stock option exercise behaviors and the contractual term of the awards. Due to our limited experience with the expected term of options, the simplified method was utilized in determining the expected option term as prescribed in ASC 718 Compensation – Stock Compensation.

We recognize our stock-based compensation expense over the requisite service period, which is generally consistent with the vesting of the awards, based on the estimated fair value of all stock-based payments issued to employees and directors that are expected to vest.

 

There have been no material changes to our critical accounting policies and estimates, except forduring the following:period covered by this report.

 

Stock-based compensation

Determining the appropriate fair value model and calculating the fair value of stock-based awards requires estimates and judgments. Our stock-based compensation is a “critical accounting estimate” because changes in the assumptions used to develop estimates of fair value or the requisite service period could materially affect key financial measures, including income (loss) from operations and net income (loss).

We use the Black-Scholes valuation model to calculate the fair value of performance-based stock options. The value is recognized as expense over the derived requisite service period beginning in the period in which they are deemed probable to vest. Vesting probability is assessed based upon certain factors and requires significant judgment.

The expected term of options granted is estimated based on a number of factors, including the vesting and expiration terms of the award and the historical volatility of our common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option award.

30-29-
 

Warrants

In conjunction with the Securities Purchase Agreement (“SPA”), we issued 18,463,511 warrants to the senior note holders. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $.7794 per share at any time on or after October 13, 2021 (the “Initial Exercise Date”) and on or prior to the close of business on October 13, 2026 the “Termination Date”). We determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the debt instruments. Management also determined that the warrants are puttable for cash upon a fundamental transaction at the option of the holder and as such required classification as equity pursuant to ASC 470. In accordance with the accounting guidance, the outstanding warrants are recognized as equity on the balance sheet. The proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) shall be allocated to the two elements based on the relative fair values of the debt instrument without the warrants, and of the warrants themselves at time of issuance. The allocation of the portion of the value resulted in a discount of the debt instrument. The fair value of the warrants were measured using the Black Scholes option pricing model.

Recently Issued Accounting Pronouncements

See Note 2 to the accompanying consolidated financial statements for a discussion of recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.

 

ItemITEM 3. Quantitative and Qualitative Disclosures About Market RiskQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company qualifies as a smaller reporting company as defined in Item 10(f)(1) of SEC Regulation S-K and is not required to provide the information required by this Item.Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

ITEM 4. CONTROLS AND PROCEDURES

Item 4.Background

Evaluation of Disclosure Controls and Procedures

i) Background

In February 2019, management was made aware, as part of the year-end sales cut-off testing procedures performed during the Company’s 2018 annual audit, by its then independent auditors, Plante & Moran, PLLC, that sales transactions may have been recognized as revenue prematurely which could have a material impact on revenue recognition for the year ended December 31, 2018. Upon such notification, management reviewed the Company’s revenue recognition reporting system, practices and underlying documents supporting the appropriateness of revenue under the Company’s previously established accounting policies for each quarterly period in the year ended December 31, 2018. In addition to the 2018 year-end period, management initially concluded that a potential material misstatement in revenue recognition was isolated to the previously issued quarterly financial statements for the three and nine months ended September 30, 2018.

Audit Committee Investigation

In March 2019, following management’s presentation of their initial assessment of the revenue recognition issue, the Audit Committee of the Board of Directors engaged independent legal counsel and a forensic accountant to conduct an investigation and to work with management to determine the potential impact on accounting for revenues. The investigation included the review of management’s initial assessment, interviews with key personnel, correspondence, and document review, among other procedures. In April 2019, as a result of the findings of the Audit Committee’s investigation to date, the Company determined that certain of its employees had engaged in deliberate inappropriate conduct, which resulted in revenue being intentionally recorded in periods prior to the criteria for revenue recognition under U.S. GAAP being satisfied. Further, the investigation discovered that revenue had been prematurely recorded in prior periods as well as the periods initially identified by management.

The investigation revealed that certain customer orders had been invoiced, triggering revenue recognition, prior to the actual shipment leaving the Company’s control. Such orders from customers had been marked as fulfilled in the Company’s enterprise reporting platform (“ERP”), thereby triggering the generation of an invoice and the recognition of revenue, in advance of shipments from both the Company’s distribution center in Tennessee and for orders that were drop-shipped directly to key customers from certain contract manufacturers. In addition, it was discovered during the investigation that certain orders had been moved to third-party locations at the respective cut-off periods and not actually shipped to the end customer until after the cut-off period resulting in the premature issuance of invoices to customers and recognition of revenue.

As a result of the Audit Committee’s investigation, certain employees were terminated, and others received written reprimands related to their conduct as a result of their behavior. In connection with the improprieties identified during the investigation resulting in the restatement of previously reported financial statements, the Company identified control deficiencies in its internal control over financial reporting that constitute material weaknesses.

The investigatory adjustments are further described in Note 16, “Changes and Correction of Errors in Previously Reported Consolidated Financial Statements” located in Item 8 of the 2019 Annual Report on Form 10-K.

31

Other Adjustments Resulting from Reconsidering Previously Issued Financial Statements

As a result of issues identified during the Audit Committee investigation, management reconsidered the Company’s previously issued consolidated financial statements and as a result, additional corrections to the Company’s previously issued consolidated financial statements for each of the quarterly reporting periods ended September 30, 2018 and for the year ended December 31, 2017 were identified. These errors, for each period presented below, were primarily due to the following:

Improper classification of trade promotions, payable to the Company’s customers, as operating expenses instead of a reduction in revenue;
Improper cut-off related to sales transactions recorded prior to transfer of control to customers in 2018 and risk of loss transferred to the customer in 2017;
Corrections of estimates of the expected value of customer payments, in the form of credits, issued to customers;
Untimely recording of the change in the estimated useful life of leasehold improvements and an asset retirement obligation related to a modification to the lease of the Company’s former headquarters;
Incorrect treatment of debt discounts related to the related-party convertible note; and
Other period-end expense cut off.

Other adjustments include, but are not limited to the following; purchase price variances, accrual for legal fees, payroll tax adjustment on restricted stock, rebate receivable and recognizing revenue on a net versus gross basis. Accumulated deficit has been adjusted to reflect changes to net loss, for each period restated.

(ii) Evaluation of disclosure controls and procedures

TheOur principal executive officer and principal financial officer have evaluated the Company’s disclosure controls and procedures as of June 30, 2021.March 31, 2022. Based on this evaluation, they concluded that because of the material weaknesses in our internal control over financial reporting discussed below, the disclosureour internal controls and procedures were not effective as required under Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Disclosure controls and procedures are designed to ensure that the information required to be disclosed by the Company in the reports that it fileswe file or submitssubmit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to ensure that information required to be disclosed by the Companyus in the reports that it fileswe file or submitssubmit under the Exchange Act is accumulated and communicated to the Company’sour management, including itsour principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(iii) Management’s reportReport on internal controlInternal Control over financial reportingFinancial Reporting

 

Management of the CompanyOur management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rule 13a-15(f). The Company’sOur internal control over financial reporting is a process affected by the Company’sour management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’sour financial statements for external purposes in accordance with U.S. GAAP.

 

In designing and evaluating our internal controls and procedures, our management recognized that internal controls and procedures, no matter how well conceived and operated, can provide only a reasonable, not absolute, assurance that the objectives of the internal controls and procedures are met. In addition, any evaluation of the effectiveness of internal controls over financial reporting in future periods is subject to risk that those internal controls may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

-30-

The Company’s

Our management assessed the effectiveness of its internal control over financial reporting as of DecemberMarch 31, 2020.2022. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission’s 2013 Internal Control-Integrated Framework. Based on its assessment, as well as factors identified during the Audit Committee investigation and subsequent audit process, management has concluded that the Company’sour internal control over financial reporting as of December 31, 20202021 was not effective due to the existence of the material weaknesses in internal control over financial reporting described below.

 

32

Material Weaknesses

(iv)

Material Weaknesses IdentifiedThe Company has deficiencies in connection with the Audit Committee Investigation.design and operation of its internal controls in the financial processes related to the accounting for cash, accounts receivable, accounts payable, inventory, accrued liabilities, income taxes, debt, equity, revenue, costs of sales, stock-based compensation, and expenses classification. In addition, the Company has insufficient controls over the financial close and reporting process, including account reconciliations and preparation and review of financial statements and related disclosures. Significant employee turnover and lack of technical expertise in the accounting function, has led to a lack of documentation and inconsistent practices in the implementation and execution of internal controls, including those at the entity level, information technology general controls, segregation of duties controls, and business process controls.

 

Based on the principal findings of the investigation conducted by the Audit Committee, management has concluded that it did not maintain an appropriate control environment, inclusive of structure and responsibility including proper segregation of duties, and risk assessment and monitoring activities which led to revenue recognition and tonal concerns and which constituted the following material weaknesses:

A.Pressure to achieve sales targets gave rise to the premature and/or inappropriate recognition of revenues, typically occurring at or near the end of financial reporting periods;
B.The Company’s internal controls failed and/or were not adequate to ensure that there was effective testing of period end sales cutoff, including a proper review and comparison of invoice dates and related proof of delivery; and
C.Inadequate segregation of duties, allowing for an improper alignment of sales and operations under common leadership.

(v) Material Weaknesses Resulting from Reconsidering Previously Issued Financial Statements.

As described above, management reconsidered the Company’s previously issued financial statements resulting in corrections to our unaudited consolidated financial statements for each of the quarterly periods ended September 30, 2018 and our audited consolidated financial statements as of and for the year ended December 31, 2017, which are contained in Note 16, “Changes and Correction of Errors in Previously Reported Consolidated Financial Statements” located in Item 8 of the 2019 Annual Report on Form 10-K filed with the SEC on August 25, 2020.

We have identified the following material weaknesses in connection with these issues:

CONTROL ENVIRONMENT AND CONTROL ACTIVITIES

Management did not maintain an effective control environment, including ensuring that required accounting methodologies, policies, and technical accounting personnel were in place. This control deficiency led to a series of corrections related to the years 2018 and 2017 and resulted in a restatement to the respective previously issued financial statements.
The Company did not properly classify payments to customers, primarily for promotional activity, as a reduction in the transaction price with its customers, instead treating such payments as an advertising and promotions activity, a component of operating expense.
The Company reported certain sales transactions prior to transfer of control of goods, inconsistent with customer sales agreements and the Company’s customary practices.
The Company did not properly estimate the expected value of customer payments, in the form of credits, at each quarter period end in 2018. In addition, the Company understated its accrual for customers’ credits for the year ended December 31, 2017.
The Company did not adjust the estimated useful life of its leasehold improvements nor an asset retirement obligation in the proper period for its former headquarters.

THE COMPANY DOES NOT MAINTAIN ADEQUATE INTERNAL CONTROL DOCUMENTATION AND TESTING PROCEDURES

The Company lacks the proper internal control documentation and testing, and therefore internal controls were not consistently performed. Management has concluded that the foregoing was attributable to several factors including the lack of finance leadership, not retaining a third-party professional Sarbanes-Oxley (“SOX”) testing consultant, and significant management turnover. Therefore, management has not documented and enforced an appropriate level of review and controls, including properly documented entity level, information technology general controls including appropriate user access controls, and business process controls.

33

Remediation

 

Our remedial actions to date and remediation plans to be undertaken in response to the findings of the Audit Committee’s investigation and the material weaknesses on internal control over financial reporting and our conclusions reached in evaluating the effectiveness of our disclosure controls and procedures and internal controls over financial reporting as of June 30,March 31, 2022 and 2021, are described below.

 

 TerminationsWe are in the process of designing and reprimandsexpect to implement, measures that we believe address or will address these control weaknesses, we continue to develop our internal controls, processes and reporting systems by, among other things, hiring qualified personnel with expertise to perform specific functions, and designing and implementing improved processes and internal controls, including ongoing senior management review and audit committee oversight. We plan to remediate the identified material weakness through the redistribution of job responsibilities, after hiring additional senior accounting staff, with additional technical accounting expertise and through the design and implementation of additional internal controls in order to promote adequate segregation of duties. Additionally, we intend to designate a member of management to review and improve our internal control processes. We expect to complete the remediation in 2022. We expect to incur additional costs to remediate the material weaknesses, primarily personnel costs for both internal and external resources.

The Company terminated certain employees directly responsible in the deliberate inappropriate conduct and other employees received written reprimands as a result of their behavior.

 ImplementationWe may not be successful in implementing these changes or in developing other internal controls, which may undermine our ability to provide accurate, timely and reliable reports on our financial and operating results. Further, we will not be able to fully assess whether the steps we are taking will remediate the material weakness in our internal control over financial reporting until we have completed our implementation efforts and sufficient time passes in order to evaluate their effectiveness. In addition, if we identify additional material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. Moreover, in the future we may engage in business transactions, such as acquisitions, reorganizations or implementation of enhanced quarterly cut-off procedures

The Company has implemented internal controls and procedures to conduct enhanced revenue recognition cut-off testing on a quarterly basis.

The Company also improved cut-off in regard to the Company’s inventory as inventory is currently maintained and controlled either by third-part manufacturers, or in a Company warehouse operated by a third-party logistics provider. This allows the Company to use inventory counts provided by independent third parties.

Mandatory training for the salesnew information systems that could negatively affect our internal control over financial reporting and operations department.

The Company has commenced a series of compliance outreach and training for its sales and operations departments relating to potential improper customer transactions identified by the internal investigation. These trainings will also include a review of the Company’s Code of Business Conduct and Ethics (the “Code of Conduct”) and the Employee Complaints & Whistleblower Policy (the “Whistleblower Policy”).

Company-wide training about compliance matters, including with respect to employee complaints and concerns and enhancement of the customer contracting process.result in material weaknesses.

 

The Company is implementing Company-wide training sessions. These sessions will focus on a number of areas related to sensitivity training/tonal concerns, including increased promotion and training around the Code of Conduct and the Whistleblower Policy. The Company will design and implement a more formalized compliance program with the goal of sustaining a culture of compliance.

Consider appropriate employment actions relating to certain employees

The Company implemented a senior leadership reorganization to strengthen the Company’s leadership team and set the company up for long term profitable growth. During 2021, the Company hired an experienced President and Chief Financial Officer with a Fortune 500 c-suite background and an experienced VP, Controller with public company reporting expertise and experience remediating material weaknesses. In addition, the Company promoted from within an SVP of sales.

Establishment of a disclosure committee

The Company is currently implementing a disclosure committee, which it expects to put in place during the third quarter of 2021, to assist the Chief Executive Officer and Chief Financial Officer in preparing the disclosures required by U.S. GAAP and U.S. Securities and Exchange Committee (SEC) rules and to help ensure that the Company’s disclosure controls and procedures are properly implemented.

Enhancing the internal compliance function, and authorizing management to retain the appropriate individual or individuals.

As part of the senior leadership reorganization referred to above, the Company is evaluating outside firms to assist in the process of revamping its internal control documentation and testing. In addition, the Company will continue to review the qualifications of our internal financial organization to ensure our personnel have the appropriate technical and SOX related expertise.

34

The Company has enhanced its Whistleblower Policy by including our Audit Committee Chair in the investigation, documentation, and resolution process.

We are committed to continuing to improve our internal control processes related to these matters and will continue to review our financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financial reporting, we may take additional measures to address deficiencies or modify certain of the remediation measures described above.

We expect thatto progress on our remediation efforts, including design and implementation, will continue through fiscal year 2021. In particular, as noted above, the Company has implemented enhanced controls regarding sales cut-off, as well as customer discounts.

Due to the considerable time and effort management of the Company undertook in order to bring its delinquent filings current, which was completed on November 24, 2020, along with turnover within the finance department and despite ongoing remediation efforts through the second quarter of 2021, the Company was not able to complete a majority of its remediation efforts during the period ended June 30, 2021.

Other than the ongoing remediation efforts described above, there have been no changes during the quarter ended June 30, 2021 in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.remainder of 2022.

 

Notwithstanding the material weaknesses described in this Item 4, our managementManagement has concluded that the consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q presents fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP. Management’s position is based on a number of factors, including, but not limited to:

 

The completion of the Audit Committee’s investigation andWith the substantial resources expended (including the use of external consultants) and the resulting adjustments we made to our previously issued financial statements, including the restatement of our 2017 audited financial statements and our unaudited quarterly financial statements for the periods ended September 30, 2018, June 30, 2018 and March 31, 2018;;
  
The reconsideration of significant accounting policies and accounting practices previously employed by the Company, resulting in other adjustments to previously issued consolidated financial statements.statements; and
Based on the actions described above, we have updated, and in some cases corrected, our accounting policies and have applied those to our consolidated financial statements for all periods presented.

 

Based on the actions described above, weChanges in Internal Control Over Financial Reporting

There have updated, andnot been any changes in some cases corrected, our accounting policies andinternal control over financial reporting during our most recent fiscal quarter that have applied thosematerially affected, or are reasonably likely to materially affect, our consolidatedinternal control over financial statements for all periods presented.reporting.

 

-31-

PART II—OTHER INFORMATION

 

ItemITEM 1. Legal ProceedingsLEGAL PROCEEDINGS

 

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. For information regarding legal proceedings, see Note 98 to the Notes to Consolidated Financial Statements (unaudited) contained herein, which is incorporated by reference into this part II, Item 1.

 

ItemITEM 1A. Risk FactorsRISK FACTORS

 

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K as amended for the year ended December 31, 2021(“Annual Report”). There have been no material changes in our risk factors from those previously disclosed in our Annual Report. You should carefully consider the risks described in our Annual Report, which could materially affect our business, financial condition or future results. The informationrisks described in our Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be reported under this Item is not required for smaller reporting companies.immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

 

ItemITEM 2. Unregistered Sales of Equity Securities and Use of ProceedsUNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

We have not made any repurchases of our common stock during the second quarter of 2021.None.

35

 

ItemITEM 3. Defaults Upon Senior SecuritiesDEFAULTS UPON SENIOR SECURITIES

 

None.

 

ItemITEM 4. Mine Safety DisclosuresMINE SAFETY DISCLOSURES

 

None.Not applicable.

 

ItemITEM 5. Other InformationOTHER INFORMATION

 

None

 

ItemITEM 6. Exhibit IndexEXHIBITS

 

Incorporated by Reference

Exhibit

No.

 DescriptionForm

SEC File

Number

ExhibitFiling Date
10.1**Letter agreement, dated May 12, 2021 between the Company and Joseph Cannata.
31.1** Certification of the ChiefPrincipal Executive Officer pursuantPursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.2002
   
31.2** Certification of the ChiefPrincipal Financial Officer pursuantPursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.2002
   
32.1*** Certification of the ChiefPrincipal Executive Officer pursuantand Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-OxleySarbanes- Oxley Act of 2002.2002
   
101.INS* Inline XBRL Instance Document
   
32.2***101.SCH* Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Inline XBRL Taxonomy Extension Schema Document
   
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
   
101**101.DEF* The following materialsInline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File - the cover page from MusclePharm Corporation’s quarterly reportthe Registrant’s Quarterly Report on Form 10-Q for the three monthsquarter ended March 31, 20212022 is formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statement of Changes in Stockholders’ Deficit; (v) the Consolidated Statements of Cash Flows; and (vi) related notes to these financial statements.

 

**Filed herewithherewith.
***Furnished herewithherewith.

36-32-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 MUSCLEPHARM CORPORATION
   
Date: AugustMay 16, 20212022By:/s/ Ryan Drexler
Ryan Drexler

Chief Executive Officer and Chairman of the Board of Directors

(Principal Executive Officer)

Date: May 16, 2022By:/s/ Sabina Rizvi
 Name:Sabina Rizvi
 Title:

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

37-33-